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ABSTRACT
Estrogen (17β-estradiol, E2) plays an important role in regulating an array
of functions in both male and female reproductive physiology. In the mammary
gland, E2-induced proliferation, ductal outgrowth and subsequent branching
morphogenesis is required for proper development of the breast. In males, E2 is
required for proper testicular development, spermatogenesis, and sperm
maturation in the epididymis, but can also negatively regulate these functions
with inappropriate exposure.
The effects of E2 in these organs have long been attributed to classical
estrogen receptors (ERα and ERβ), due to the observed effects in ER-/- mice;
however, GPER is abundantly expressed in male and female reproductive
organs, including the breast, testes and epididymis, and there is increasing
evidence that GPER contributes to E2-induced functions in these tissues. For
this study, we were interested in the contribution of GPER to E2-induced
processes in 1) the breast; proliferation and morphogenesis, 2) the testes;
regulation of spermatogenesis and morphology, and 3) the epididymis;
specifically morphological regulation.
Since proliferation and morphogenesis in the mammary gland are under
tight E2 control and GPER is able mediated E2-induced proliferation in breast
cancer cells, we were interested to see if GPER mediates E2-induced
proliferation and morphogenesis in breast epithelial cells (MCF10A cell line) and
in human breast tissue. E2 and G-1 stimulation in human breast tissue led to
significant increase in proliferation measured by Ki-67 staining, and led to distinct
vii

morphological changes including an E2-induced increase in epithelial height in
alveolar structures and a G-1-induced increase in luminal area after seven days
in culture. E2-and G-1 also stimulated proliferation in MCF10A cells and this is
dependent on epidermal growth factor receptor (EGFR) transactivation and
mitogen activated protein kinase (MAPK) activation. Other observations in
chapter 3, including a G-1-induced reduction in E-cadherin protein expression
(breast tissue) and a G-1-induced increase in focal adhesion kinase (FAK)
activation

(MCF10A

cells)

suggest

that

regulation

of

GPER-mediated

morphological changes involves regulation of cell-cell adhesion proteins.
To determine the contribution of GPER to E2-induced spermatogenesis
and morphology in male reproductive organs, we subcutaneously implanted
C57BL/6 male mice with 21-day release E2 and G-1 pellets, and then
investigated morphological effects on the testes and epididymis. G-1 had no
effect on spermatogenesis or testicular morphology (unlike estrogen which
impairs proper testicular morphology and abolishes spermatogenesis); however,
G-1 treatment significantly increased the luminal area of epithelial structures in
the epididymis.
We have demonstrated in this study that while GPER doesn’t mediate the
entirety of estrogen’s effect in female and male reproductive physiology, GPERcontributes to E2-induced proliferation in the mammary gland and to the
regulation of morphogenesis of epithelial structures in the breast and the
epididymis.

viii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS .................................................................................... v
ABSTRACT ........................................................................................................ vii
TABLE OF CONTENTS ...................................................................................... ix
LIST OF FIGURES ............................................................................................. xii
ABBREVIATIONS ............................................................................................. xiv
1. INTRODUCTION .............................................................................................. 1
1.1 Estrogens............................................................................................................................... 1
1.1.1 Estrogen function in human physiology ......................................................................... 2
1.2 Classical estrogen receptor signaling .................................................................................... 2
1.2.1 Non-genomic signaling through classical estrogen receptors ........................................ 3
1.2.2 Classical estrogen receptors in mammary gland biology ............................................... 4
1.2.3 Estrogens in male physiology......................................................................................... 6
1.3 G protein-coupled estrogen receptor (GPER/GPR30) .......................................................... 8
1.3.1 GPER signaling .............................................................................................................. 9
1.3.2 GPER-selective compounds ........................................................................................ 11
1.4 Estrogen and breast cancer ................................................................................................ 13
1.5 Rationale for project ............................................................................................................ 14
1.6 Hypothesis ........................................................................................................................... 16
1.6.1 Specific Aims ................................................................................................................ 17
1.7 Figure legends ..................................................................................................................... 18
1.8 Figures ................................................................................................................................. 20

2. Estrogen-induced activation of GPER and downstream proliferative
signaling ............................................................................................................ 25
2.1 Abstract................................................................................................................................ 25
2.2 Introduction .......................................................................................................................... 27
2.3 Results ................................................................................................................................. 31
2.3.1 Estrogen induces proliferation in MCF10A cells .......................................................... 31
2.3.2 MCF10A cells express GPER ...................................................................................... 31
2.3.3 Estrogen-induced proliferation is mediated by GPER in MCF10A cells ...................... 32
2.3.4 E2 and G-1 induce ERK activation in MCF10A cells ................................................... 33
2.3.5 Mechanism of E2- and G-1-induced ERK activation in MCF10A cells ........................ 34
2.3.6 Mechanism of E2- and G-1-induced proliferation in MCF10A cells ............................. 37
2.3.7 E2 and G-1 induce proliferation in a 3-D model of breast morphogenesis .................. 38
2.3.8 GPER contributes to E2-induced proliferation in human breast tissue ........................ 39

ix

2.3.9 E2 and G-1 promote proliferation in tumorigenic human breast tissue ........................ 40
2.4 Discussion ........................................................................................................................... 41
2.5 Materials and Methods ........................................................................................................ 45
2.5.1 Reagents ...................................................................................................................... 45
2.5.2 Inhibitors and antibodies .............................................................................................. 45
2.5.3 Cell Culture ................................................................................................................... 46
2.5.4 Tissue Samples ............................................................................................................ 48
2.5.5 Organ Culture ............................................................................................................... 48
2.5.6 Indirect Immunofluorescence (Tissue) ......................................................................... 49
2.5.7 Western Immunoblotting .............................................................................................. 50
2.5.8 Quantitation .................................................................................................................. 51
2.5.9 Statistical Analysis ........................................................................................................ 51
2.6 Figure Legends .................................................................................................................... 52
2.7 Figures ................................................................................................................................. 58

3. ESTROGEN REGULATION OF CELL DIVISON ORIENTATION AND
ALVEOLAR MORPHOLOGY IN THE MAMMARY GLAND .............................. 73
3.1 Abstract................................................................................................................................ 73
3.2 Introduction .......................................................................................................................... 75
3.3 Results ................................................................................................................................. 82
3.3.1 Estrogen and G-1 induce distinct morphological changes in breast tissue ................. 82
3.3.2 Estrogen and G-1 treatment of MCF10A cells alters mitotic spindle orientation in a 3-D
environment ........................................................................................................................... 85
3.3.3 Activation of GPER in human breast tissue decreases E-cadherin protein expression
at epithelial junctions in human breast tissue ........................................................................ 86
3.3.4 Activation of GPER increases FAK phosphorylation in MCF10A cells ........................ 88
3.4 Discussion ........................................................................................................................... 90
3.5 Materials and Methods ........................................................................................................ 96
3.5.1 Reagents ...................................................................................................................... 96
3.5.2 Inhibitors and antibodies .............................................................................................. 96
3.5.3 Cell Culture ................................................................................................................... 97
3.5.4 Tissue Samples ............................................................................................................ 98
3.5.5 Organ Culture ............................................................................................................... 99
3.5.6 Tissue histology and Image Analysis ........................................................................... 99
3.5.7 Indirect Immunofluorescence (Tissue) ....................................................................... 100
3.5.8 Western Immunoblotting ............................................................................................ 101
3.5.9 Cell Imaging and image analysis................................................................................ 102
3.5.10 Statistical analysis .................................................................................................... 102

x

3.6 Figure Legends .................................................................................................................. 103
3.7 Figures ............................................................................................................................... 107

4. GPER REGULATION OF MALE REPRODUCTIVE PHYSIOLOGY ............ 119
4.1 Abstract.............................................................................................................................. 119
4.2 Introduction ........................................................................................................................ 121
4.3 Results ............................................................................................................................... 126
4.3.1 Pubertal exposure to estrogen reduces testes size and wet weight in mice. ............ 126
4.3.2 Estrogen disrupts testicular morphology and spermatogenesis in male mice. .......... 126
4.3.3 G-1 promotes increase epididymal lumen size in male mice ..................................... 127
4.4 Discussion ......................................................................................................................... 129
4.5 Materials and Methods ...................................................................................................... 132
4.5.1 Mouse Models ............................................................................................................ 132
4.5.2 Histology ..................................................................................................................... 132
4.5.3 Morphologic evaluation of Epididymal Lumens .......................................................... 132
4.5.4 Testes Wet Weight/Sperm Quantification .................................................................. 133
4.5.5 Statistical Analysis ...................................................................................................... 133
4.6 FIGURE LEGENDS ........................................................................................................... 134
4.7 Figures ............................................................................................................................... 139

5. SUMMARY AND FUTURE DIRECTIONS .................................................... 148
5.1 Summary ........................................................................................................................... 148
5.1.1 Chapter 2 .................................................................................................................... 148
5.1.2 Chapter 3 .................................................................................................................... 150
5.1.3 Chapter 4 .................................................................................................................... 151
5.2 OVERALL CONCLUSIONS............................................................................................... 154

REFERENCES ................................................................................................. 155

xi

LIST OF FIGURES
Figure 1.1 Regulation of 17β-estradiol production by the hypothalamic-pituitary-gonadal axis .... 20
Figure 1.2 Conversion of cholesterol to 17β-estradiol occurs in the ovary .................................... 21
Figure 1.3 Estrogen activation of classical estrogen receptors ERα/β .......................................... 22
Figure 1.4 GPER-dependent signaling .......................................................................................... 23
Figure 1.5 GPER Selective Compounds........................................................................................ 24
Figure 2.1 17-β Estradiol stimulates proliferation in MCF10A cells ............................................... 58
Figure 2.2 MCF10A cells express GPER....................................................................................... 59
Figure 2.3 E2 and G-1-induced proliferation is dependent on GPER in MCF10A cells ................ 60
Figure 2.3 E2 and G-1-induced proliferation is dependent on GPER in MCF10A cells ................ 61
Figure 2.4 GPER activation induces activation of the MAPK signaling cascade........................... 62
Figure 2.4 GPER activation induces activation of the MAPK signaling cascade........................... 63
Figure 2.5 GPER-dependent activation of MAPK (ERK1 and ERK2) is dependent on Src
activation but not MMP activation in MCF10A cells. ......................................................... 64
Figure 2.5 GPER-dependent transactivation of the EGFR is dependent on Src activation but not
MMP activation in MCF10A cells. ..................................................................................... 65
Figure 2.6 GPER-dependent proliferation requires transactivation of the EGFR. ......................... 66
Figure 2.7 Illustration of MCF10A 3-D culture method .................................................................. 67
Figure 2.8 Estrogen-induced GPER activation stimulates proliferation in a 3-dimensional model of
breast morphogenesis ...................................................................................................... 68
Figure 2.9 Illustration of human breast tissue culture method ....................................................... 69
Figure 2.10 E2 and G-1 promote proliferation in human breast tissue .......................................... 70
Figure 2.10 E2 and G-1 promote proliferation in human breast tissue .......................................... 71
Figure 2.11 E2 and G-1 promote proliferation in tumorigenic human breast tissue ...................... 72
Figure 3.1 Mitotic spindle orientation in adherent epithelial cells ................................................ 107
Figure 3.2 Illustration of a human mammary gland duct in cross section.................................... 108
Figure 3.3a E2 and G-1 treatment of human breast tissue results in increased epithelial height
and luminal area.............................................................................................................. 109

xii

Figure 3.3b E2 and G-1 treatment of human breast tissue results in increased epithelial height
and luminal area.............................................................................................................. 110
Figure 3.4 Hypothetical effect of mitotic spindle orientation on alveolar morphology in breast
tissue ............................................................................................................................... 112
Figure 3.5 MCF10A model of breast morphogenesis .................................................................. 113
Figure 3.6 Estrogen leads to a rotation of the mitotic spindle in MCF10A cells grown in Matrigel™
........................................................................................................................................ 114
Figure 3.7 E-cadherin in mammary alveolar structures. .............................................................. 115
Figure 3.8 G-1 downregulates E-cadherin expression in human breast tissue ........................... 116
Figure 3.8 G-1 downregulates E-cadherin expression in human breast tissue ........................... 117
Figure 3.9 G-1 induces FAK activation in MCF10A cells ............................................................. 118
Figure 4.1 Endocrine regulation of testicular cells by the hypothalamic-pituitary-gonadal axis .. 139
Figure 4.2 Cross-sectional structure of a mouse seminiferous tubule......................................... 140
Figure 4.3 Illustration of mouse epididymis.................................................................................. 141
Figure 4.4 Estrogen reduces testes size in male C57BL/6 mice ................................................. 142
Figure 4.5 Estrogen reduces testes wet weight in male C57BL/6 mice ...................................... 143
Figure 4.6 Estrogen disrupts testicular morphology and spermatogenesis in male C57BL/6 mice
........................................................................................................................................ 144
Figure 4.7 Estrogen disrupts spermatogenesis in male C57BL/6 mice ....................................... 145
Figure 4.8a G-1 induces an increase in lumen size in male C57BL/6 epididymis ....................... 146
Figure 4.8b G-1 induces an increase in lumen size in male C57BL/6 epididymis mouse
epididymis ....................................................................................................................... 147

xiii

ABBREVIATIONS
2-D—2 dimensional
3-D—3 dimensional
ADAM—a disentegrin and metalloprotease
ATCC—American type culture collection
BAX—BCL-associated X protein
BCL2—B-cell lymphoma 2
BM—basement membrane
BSA—bovine serum albumin
CHTN—cooperative human tissue network
DAPI—4',6-diamidino-2-phenylindole
DCIS—Ductal Carcinoma In Situ
DMEM—Dulbecco’s modified eagle medium
DN—dominant negative
E2—17β-estradiol
ECM—extracellular matrix
EGF—epidermal growth factor
EGFR—epidermal growth factor receptor
ER—estrogen receptor
ERE—estrogen response element
ERK—extracellular signal-regulated kinases
ERα—estrogen receptor α
ERβ—estrogen receptor β
FAK—focal adhesion kinase
FBS—fetal bovine serum
xiv

FSH—follicle stimulating hormone
G1—Gap 1 phase of mitosis cell cycle
G-1—GPER-selecitve compound 1 (agonist)
G15—GPER-selective compound 15 (antagonist)
G36—GPER-selective compound 36 (antagonist)
GnRH—gonadatrophin releasing hormone
GPCR—G protein-coupled receptor
GPER—G protein-coupled estrogen receptor
GPR30—G protein-couple receptor 30
HB-EGF—heparin-bound epidermal growth factor
HER2—human epidermal growth factor receptor 2
hr—hour
HSP—heat shock protein
IBC—inflammatory breast cancer
IGFR—Insulin-like growth factor receptor
LH—luteinizing hormone
MAPK—mitogen-activated protein kinase
MEC—mammary epithelial cell
MEK—MAP kinase kinase
min—minute
MMP-matrix metalloprotease
NGS—normal goat serum
NIH—National Institutes of Health
NS—not significant
PBS—Phosphate buffered saline
xv

PFA—paraformaldehyde
PH—pleckstrin homology
PH3—phospho-histone H3 antibody
PH-FP—pleckstrin homology conjugated fluorescent protein
PI3K—phosphoinositide 3-kinase
PIP3--phosphatidylinositol (3,4,5)-trisphosphate
PLC—phospholipase C
PKA—protein kinase A
PKC—protein kinase C
PM—plasma membrane
RT-PCR—reverse transcriptase polymerase chain reaction
SERM—selective estrogen receptor modulator
siRNA—small interfering ribonucleic acid
TBS—tris buffered saline
TBST—tris buffered saline with 1% Tween-20

xvi

1. INTRODUCTION
1.1 Estrogens
The estrogen family of steroid hormones regulates a wide variety of
physiological processes within the human body. There are three estrogens that
exert an effect at different times throughout female reproductive physiology;
estriol, estrone and 17β-estradiol (estradiol, E2), the latter being the most
biologically active estrogenic hormone in non-pregnant women between
menarche and menopause (Anderson, 2002). Estrogens belong to the family of
steroid hormones that include progesterone, testosterone, glucocorticoids and
mineralcorticoids. Being a steroid hormone, estrogens are derived from
cholesterol and ultimately synthesized by aromatization of testosterone.
Biosynthesis of estrogens is regulated by the hypothalamic-pituitary-gonadal axis
(Fig 1.1) (Bliss et al., 2010; McLachlan, 2000). Gonadotrophin releasing
hormone (GnRH) is released from the hypothalamus which stimulates cells in the
anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating
hormone (FSH). LH acts on the theca interna cells in the ovary, to stimulate the
conversion of cholesterol to progesterone, and finally to androstenedione.
Androstenedione then enters neighboring granulosa cells in the ovary, where
FSH stimulates its conversion to testosterone (McLachlan, 2000). Testosterone
is converted via aromatase into 17β-estradiol (E2) (Fig 1.2). E2 produced by the
ovaries in turn acts on cells of the anterior pituitary, which regulate LH and FSH
secretion, creating a negative feedback loop (McLachlan, 2000). In premenopausal women, E2 is produced primarily by granulosa cells in the
1

developing ovarian follicles, the corpus luteum and the placenta (Nelson and
Bulun, 2001). E2 is also produced in smaller amounts by other tissues such as
the adrenal glands, the liver, the breasts, and adipose tissue supported by the
localization of aromatase expression in these tissues (Nelson and Bulun, 2001).
E2 production in local tissues (other than the ovaries) is especially important in
postmenopausal women, when ovarian function ceases (Nelson and Bulun,
2001).

1.1.1 Estrogen function in human physiology
E2 regulates a wide range of physiologic processes in many tissue types
in both men and women. While E2 is traditionally thought of as a female sex
hormone, there are many targeted effects of E2 throughout the body distinct from
its role in development and maintenance of female reproductive organs. For
example, E2 plays a role in cardioprotection (Guzzo, 2000), neuroprotection
(Arnold and Beyer, 2009) inflammation (Dai et al., 2009) and maintenance of the
skeletal system (Manolagas et al., 2002; Termine and Wong, 1998).

1.2 Classical estrogen receptor signaling
The biological effects of E2 have long been attributed to the two classical
estrogen receptors (ERs), estrogen receptor alpha (ERα) and estrogen receptor
beta (ERβ). These receptors belong to the nuclear receptor superfamily, a family
of ligand-dependent transcription factors. In the absence of ligand, ERs are
localized largely in the nucleus (with a small percentage of cytoplasmic
localization), where heat shock protein chaperones keep the receptors in an
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inactive conformation. E2 binding induces conformational changes in these
receptors, leading to the dissociation of inactivating proteins, dimerization and
translocation of cytoplasmic receptors to the nucleus. Activated ERs bind to
specific estrogen response elements (EREs) located within the promoter region
of estrogen-regulated genes (Fig 1.3). Subsequently, ERs modulate transcription
of estrogen-responsive genes, thus they mediate long-term or genomic estrogen
signaling. Although products of different genes, ERα and ERβ share a high
degree of sequence homology within their DNA binding domains (Couse and
Korach, 1999; Korach, 1994); therefore is it not surprising that both receptors are
able to bind EREs with similar specificity and affinity.

1.2.1 Non-genomic signaling through classical estrogen receptors
In addition to E2’s ability to directly regulate gene transcription, E2 is
known to induce rapid, non-genomic signaling in various cell types. These effects
are insensitive to transcriptional and translational inhibition, and occur much
faster than genomic signaling, on a scale of seconds to minutes. The rapid
effects of E2 include activation of protein kinases (extracellular signal-related
kinase (ERK, protein kinase A (PKA), protein kinase C (PKC) and
phosphoinositide-3-kinase (PI3K)), production of second messengers such as
cAMP and nitric oxide (NO) and changes in ion channel activity and intracellular
calcium (Ca2+) levels (Levin, 2002). One of the earliest reports of rapid
nongenomic E2-dependent activity was demonstrated in the 1970’s, showing that
17β-estradiol induced a rapid stimulation of cAMP production and calcium flux in
the rat endometrium (Pietras et al., 1975). Rapid, non-transcriptional E2 signaling
3

is mediated by classical ERs in their traditional locations (nucleus and
cytoplasm), yet there is also evidence for the plasma membrane localization of
classical ERs, which may also contribute to rapid signaling (Levin, 2002). ERα
specifically has been shown to mediate E2-activation of MAPK (ERK-1 and ERK2) in MCF-7 breast cancer cells as well as in Cos cells transfected with ERα
cDNA (Levin, 2003; Pedram et al., 2006; Razandi et al., 2003).

1.2.2 Classical estrogen receptors in mammary gland biology
The mammary gland is a unique organ with regard to development,
maintaining a very rudimentary structure from birth to the onset of puberty
(Silberstein, 2001), wherein exposure to circulating E2 promotes continued
development. In both humans and lower mammals, exposure to E2 causes the
mammary gland to undergo proliferation, duct elongation and lateral ductal
branching (Brisken and O'Malley, 2010). These effects are reported to be
mediated by ERα, which is not surprising since ERα is abundantly expressed in
mammary tissue (Brisken and O’Malley, 2010). ERβ is also expressed
throughout the mammary gland and plays a role in mammary gland
development. Although ERα and ERβ share similar mechanisms of action with
regard to genomic E2 signaling, studies in mice with genetic deletion of either
ERα or ERβ have revealed distinct phenotypes, suggesting these receptors
regulate dissimilar cellular pathways in the breast. ERα-/- mice maintain a very
rudimentary, neonatal mammary structure with no ductal elongation in response
to E2, suggesting ERα is the key mediator of estrogenic effects on the mammary
gland (Brisken and O’Malley, 2010). Grafting experiments with ERα-/- mice show
4

that epithelial ERα is required for ductal elongation in during puberty-associated
development in the mammary gland (Couse and Korach, 1999). In contrast,
mammary gland development occurs normally in ERβ-/- , which is responsible for
terminal differentiation, and preparation of the mammary gland for lactation
(Forster et al., 2002b).
In the human breast, estrogen receptor expression is similar to that seen
in rodents. ERα is expressed in 15-30% of the luminal epithelial cells, whereas
ERβ is present in most luminal epithelial and myoepithelial cells, as well as
stromal cells. In humans, most breast epithelial proliferation occurs in ERα
negative cells. Because ERα is rapidly degraded by the proteosome upon
activation, it was proposed that ERα expression is down modulated in cells that
have entered the cell cycle due to estrogen stimulation. To test this hypothesis
ERα null murine mammary epithelial cells (MECs) were mixed with wild type
MECs, and used to reconstitute a cleared mouse mammary fat pad. It was
demonstrated that in the presence of wt MECs, ERα null cells were able to
proliferate, indicating that estrogen promotes proliferation via a paracrine
mechanism (Mallepell et al., 2006). This result is consistent with observations in
human breast epithelia, demonstrating that the cells that proliferate do not
express ERα (Brisken and O'Malley, 2010).
The estrogen-induced paracrine mechanism that promotes proliferation is
likely mediated by amphiregulin, an EGF family member whose transcription is
strongly induced by E2 (McBryan et al., 2008). Amphiregulin is a membranebound growth factor protein that is cleaved and released by a disentegrin and
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metalloproteinase (ADAM) at the cell surface (McBryan et al., 2008; Willmarth
and Ethier, 2006a). Cleaved amphiregulin binds to and activates the epidermal
growth receptor (EGFR) on adjacent, ERα negative cells in the mammary gland,
leading to EGFR signaling, and proliferation and subsequent ductal elongation
(Brisken and O'Malley, 2010). In cells that co-express ERα and ERβ, ERβ acts to
inhibit ERα-induced proliferation. This is thought to be due to the ability of ERβ to
repress ERα-mediated cyclin D1 induction in response to estrogen, thus ERβ
mediates an anti-proliferative role in the breast (Boonyaratanakornkit and
Edwards, 2004; Liu et al., 2002). Directly coupled to its effect on epithelial
proliferation in the developing mammary gland, E2 stimulates branching
morphogenesis in the mammary gland, induced by ERα-mediated cell
proliferation (Feng et al., 2007; Mallepell et al., 2006; Silberstein, 2001).

1.2.3 Estrogens in male physiology
Although androgen (testosterone) is the dominant male sex hormone, E2
does have an important role in the male reproductive system (Carreau et al.,
2012). The effect of E2 on the male testes was demonstrated as early as the
1930’s and 40’s, when it was reported that high dose E2 exposure during
development induced malformation of components of the male reproductive
system (McLachlan, 2000). The role of E2 in male physiology became more
relevant with the description and characterization of direct binding of E2 to a
receptor (ERα) in mammalian testes and epididymis (Danzo et al., 1975; Danzo
et al., 1977; Danzo et al., 1978; Danzo and Eller, 1979).
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The role of E2 in spermatogenesis, and resultant fertility, was first
demonstrated in studies with mice lacking ERα or aromatase. These mice exhibit
impaired spermatogenesis and fertility (Korach, 1994; Lubahn et al., 1993),
highlighting the effects of E2 on male reproductive physiology. Another indication
of E2’s importance in spermatogenesis is the correlation between exposure to
environmental estrognens and decreased sperm counts in men over the past 60
years (Sharpe and Skakkebaek, 1993; Toppari et al., 1996).
E2’s regulation of spermatogenesis stems from its ability to negatively
regulate GnRH and FSH/LH secretion, similar to testosterone, as part of the
hypothalamic-pituitary testicular axis (Handelsman et al., 2000). Studies in
humans showed that administration of E2 could further enhance FSH/LH
suppression that was induced by testosterone (Handelsman et al., 2000). The
effects of E2 in the epididymis, where it is involved in sperm maturation
(achievement of sperm motility) and the resorption of fluid through the efferent
ductuals have also been demonstrated in ERα null mice (Hess et al., 1997).
The contribution of ERα to E2’s actions in the male reproductive system
were demonstrated in ERα null mice; however, in light of the discovery and of a
novel estrogen receptor, G protein-coupled estrogen receptor (GPER), recent
work has been devoted to the characterization of GPER in the male reproductive
system, including expression patterns (Lazari et al., 2009; Rago et al., 2011) and
signaling mechanisms (Chimento et al., 2011; Lucas et al., 2010). These will be
reviewed in more detail in chapter four.
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1.3 G protein-coupled estrogen receptor (GPER/GPR30)
In addition to E2 signaling mediated by classical ERs, ERα and ERβ, there
is now a third estrogen receptor reported to mediate the effects of E2 in many
different cells and tissues. The G protein-coupled estrogen receptor (GPER,
originally named GPR30) is a seven transmembrane G protein-coupled receptor
(GPCR) that binds and is activated by E2 (Carmeci et al., 1997). GPER was first
cloned in the late 1990’s by four different labs (Carmeci et al., 1997; O’Dowd et
al., 1998; Owman et al., 1996; Takada et al., 1997). One lab cloned GPER from
an ERα/β positive breast cancer cell line (MCF7) and they demonstrated that
GPER is ubiquitously expressed in normal human tissues and primary breast
carcinomas, and it’s expression overlapped with that of classical ERα (Carmeci
et al., 1997). The patterns of GPER expression indicated this receptor may be
involved in physiologic responses specific to hormonally regulated tissue
(Carmeci et al., 1997); however, at the time no natural ligand was known for this
receptor, and it was given the orphan designation GPR30 (Carmeci et al., 1997).
In 2000, work performed by a group at Brown University, led by Edward
Filardo, demonstrated E2-induced phosphorylation of ERK in breast cancer cells
lacking classical ERs (Filardo et al., 2000). It was also observed that when GPER
was expressed in ERα-, GPER-negative MDA-MB-231 breast cancer cells, they
became

increasingly

E2-responsive

in

terms

of

E2-induced

ERK

phosphorylation, while this response was lacking in wild type MDA-MB-231 cells
(Filardo et al., 2000). A similar effect of E2-responsiveness was observed in
SKBr3 breast cancer cells, which express GPER but lack classical ERs (Filardo
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et al., 2000). Inhibition of EGFR kinase function, neutralization of HB-EGF
activity, and down modulation of HB-EGF at the cell surface demonstrated that
E2-induced ERK activation was due to transactivation of the EGFR through
cleavage of HB-EGF at the cell surface by (Filardo et al., 2000). Since GPER
positive cells had been shown to be responsive to E2, the next step was to show
specific binding of E2 to GPER.
The direct binding of E2 to GPER was shown in two studies in 2005.
Revankar, et al. demonstrated direct E2 binding to GPER using fluorescently
conjugated E2 in ER-negative Cos7 cell membranes transfected with GPER
(Revankar et al., 2005). Revankar and colleagues also showed that GPER was
localized to the endoplasmic reticulum (Revankar et al., 2005), unlike other 7TM
GPCRs that are normally found at the plasma membrane. The intracellular
localization for GPER is possible because the ligand, E2, is a steroid hormone
that is able to pass freely through the membrane. At the same time, Thomas and
colleagues at Brown University described the specific binding of tritiated E2 to
ERα/β negative, GPER positive SKBr3 cell membranes, and human embryonic
kidney cells transfected with GPER (Thomas et al., 2005).

1.3.1 GPER signaling
When GPER was initially characterized, transactivation of the epidermal
growth factor receptor (EGFR) and subsequent activation of MAPK signaling in
breast cancer cells were identified as key downstream events of GPER activation
(Filardo et al., 2000); however, it had also been shown that these events could
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be mediated by ERα (Razandi et al., 2003). Clearly it became important to
determine the E2-induced signaling potentials and the mechanism by which
GPER and ERα mediate E2 signaling independently. To address this question,
Revankar et al, transfected Cos7 cells (lacking all known estrogen receptors)
with either GPER or ERα, together with a fluorescently labeled reporter for
EGFR-dependent signaling, the pleckstrin homology (PH) domain from Akt. This
reporter protein serves as an indication of PI3K signaling and membrane
localized phosphatidylinositol (3,4,5)-triphosphate (PIP3) accumulation. To
demonstrate the fidelity of the reporter for EGFR activation, cells expressing the
fluorescent reporter (PH-FP) were stimulated with epidermal growth factor (EGF).
As expected, with EGF stimulation, PH-FP accumulated at the plasma
membrane (Revankar et al., 2005). Upon E2 stimulation, cells expressing ERα or
GPER showed specific accumulation of the PH-FP reporter; however, it was
localized to the nucleus. Nuclear PH-FP accumulation was prevented by the
PI3K inhibitor LY2940092. In order to determine if different ligands distinctively
activate the two receptors, ERα or GPER transfected cells were treated with 4hydroxytamoxifen (4-HT), a selective estrogen receptor modulator (SERM),
shown to be a partial agonist against ERα and capable of activating ERK
phosphorylation via GPER. Stimulation with 4-HT had no effect in cells
transfected with ERα together with the PH-FP reporter (Revankar et al., 2005);
however, 4-HT did activate nuclear PH-FP accumulation via PI3K in GPER
expressing Cos7 cells, demonstrating that one ligand can produce different
downstream signaling events via ERα versus GPER (Revankar et al., 2005).

10

When cells were pretreated with the EGFR inhibitor AG1478, GPER-induced but
not ERα-induced PI3K activation was blocked, demonstrating again that E2 can
activate PI3K via two distinct mechanisms depending on specific receptor
expression (Revankar et al., 2005).
Taking these results together with Filardo’s initial observations, the
signaling pathway downstream of E2-dependent GPER activation is shown in
figure 1.4 (taken from Prossnitz et al., 2008). E2, being cell permeable, is able to
pass through the membrane and bind intracellular GPER located on the
endoplasmic reticulum. Upon E2 binding, GPER is activated along with its
associated heterotrimeric G proteins, which in turn can activate Src. Activated
Src can activate MMPs at the cell surface which cleave pro-HB-EGF from the cell
membrane, allowing cleaved HB-EGF to bind to and activate the EGFR, leading
to downstream activation of MAPK and PI3K activation and associated cellular
process such as proliferative and pro-survival signaling (Filardo et al., 2000;
Prossnitz et al., 2008). Quinn et al. recently demonstrated that the GPERinduced transactivation of the EGFR by HB-EGF was also dependent on α5β1
integrin activation and fibronectin matrix assembly SKBr3 breast cancer cells
(Quinn et al., 2009).

1.3.2 GPER-selective compounds
Since E2 is able to bind and activate all three known estrogen receptors
including ERα, ERβ and GPER, and both tamoxifen and ICI 182 780
(chemotherapies used as ERα down-modulators in breast cancer) have been
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shown to agonize GPER, the identification of GPER-selective compounds was
vital to facilitate further study of GPER specifically (Fig 1.5)
In an attempt to identify ligands specific to GPER, Bologa et al carried out
a virtual screen of a library of approximately 10,000 GPCR-associated
compounds to assess their structural similarity to E2. Based on the results, the
top 100 compounds were tested for activity toward GPER using a competition
binding assay. One compound, later named G-1, was subsequently identified as
a selective GPER agonist (Bologa et al., 2006). G-1 competitively displaced
binding of fluorescent E2 (E2-Alexa) in GPER-transfected cells, yielded an
inhibition constant (Ki) for G-1 of 11nM, whereas the Ki for E2 binding to GPER is
5.7nM (Bologa et al., 2006). No significant affinity of G-1 for ERα or ERβ was
observed. The specificity of G-1 as an agonist was confirmed by its ability to
promote intracellular calcium immobilization in GPER-expressing Cos7 cells, but
not cells expressing ERα/β (Bologa et al., 2006). Not long after the identification
of G-1, a GPER-selective antagonist, G15 was identified. G-15 antagonizes E2dependent GPER activation in vitro and in vivo, using a well-established assay of
E2-induced murine uterine proliferation (Dennis et al., 2009). At concentrations of
10µM and above, G15 exhibits low-affinity cross reactivity to ERα, therefore an
antagonist with enhanced selectivity to GPER, G36, was synthesized (Dennis et
al., 2011). The identification of a GPER-selective agonist and antagonist provide
us with the opportunity to selectively modulate GPER receptor function in vitro
and in vivo.
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1.4 Estrogen and breast cancer
In normal breast epithelia, 15-30% of epithelial cells express ERα,
whereas the number of ERα-positive breast epithelia increases early in malignant
progression to 60-70% (Brisken and O’Malley, 2010). As a result, in
approximately two-thirds of women who have ER positive breast cancer, E2
stimulates proliferation and thus progression of tumorigenesis (Early Breast
Cancer Trialists' Collaborative Group (EBCTCG), 2005). In these patients,
Tamoxifen, a selective estrogen receptor modulator (SERM) is used to
antagonize the binding of E2 to classical ERs, a successful strategy in
attenuating the growth of ER positive breast cancer (Fisher et al., 2005).
Tamoxifen and other SERMs have been shown to bind to and activate GPER
(Ignatov et al., 2010; Vivacqua et al., 2006b), providing a possible mechanism for
the progression of ER negative breast cancers.
In addition to GPER expression in breast cancer cell lines, GPER
expression has also been observed and correlated with decreased survival in
patients with hormone responsive cancers including breast (Arias-Pulido et al.,
2010; Filardo et al., 2006; Kuo et al., 2007; Luo et al., 2011), endometrial (Smith
et al., 2007) and ovarian (Smith et al., 2009). In a large study carried out in 2006
by Filardo et al. it was found that GPER expression in tumors was positively
correlated with HER-2/neu growth factor receptor expression, tumor size and
distant metastasis (Filardo et al., 2006), indicating GPER was an indicator of a
more aggressive form of breast cancer. In this same study it was observed that
approximately half of the ER negative breast tumors retained GPER expression
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(Filardo et al., 2006), which may suggest that these tumors remain E2 responsive
through GPER-associated signaling even in the absence of classical ERα
signaling. This hypothesis highlights the possibility of the ability to antagonize
GPER in conjunction with classical ERs in breast and other hormone responsive
cancers to achieve a better treatment outcome.

1.5 Rationale for project
Although attempts to characterize GPER have increased exponentially
since its initial discovery, the effects of GPER on breast proliferation and
morphogenesis still need to be elucidated. It is well accepted that E2 is required
for normal breast development and maintenance of proper mammary gland
function (Couse and Korach, 1999; Forster et al., 2002b). E2 is a potent mitogen
capable of promoting proliferation, both during development as well as in the
maintenance of normal mammary gland physiology. E2’s actions are mediated
by modulation of gene transcription as well as activation of rapid signaling
pathways (Kelly and Levin, 2001; Pedram et al., 2006). E2’s capacity to promote
proliferation is not limited to a phenotypically normal setting, as E2 is able to
induce proliferation in breast tumors (Brisken and O'Malley, 2010), thereby
promoting breast cancer progression. Because of E2’s role in breast
development and breast cancer, our ability to understand E2-induced physiologic
processes mediated by all three estrogen (ERα, ERβ and GPER) receptors is
vital. E2-induced processes in the body are generally attributed to the classical
estrogen receptors, ERα and ERβ; however the identification of GPER as an
estrogen receptor has complicated our understanding of E2 physiology. GPER
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has been shown to produce confounding outcomes in response to SERMs such
as tamoxifen and ICI 182, 780. These compounds function as ERα antagonists in
the breast; however they are able to activate GPER, complicating the outcome
when they are used therapeutically in patients with ER positive breast cancers
that could presumably also express GPER (Pandey et al., 2009). It has also been
shown that GPER-associated signaling pathways regulate cell proliferation,
invasion, metastasis and other tumor-related cellular signaling. In addition to
signaling, GPER may serve as a valuable predictor of cancer development and
overall prognosis in E2-dependent cancers, such as breast, due to the fact that
GPER expression is correlated with decreased survival, increased tumor size
and distant metastasis (Filardo et al., 2006). Because of the correlation between
GPER expression in breast tumors and tumor progression variables, and the fact
that GPER is activated by two widely used ER antagonists, the ability to target
this receptor in conjunction with classical ER therapy could prove to be very
successful in patients with breast cancer. In addition, since ER negative breast
cancers have a worse prognosis and fewer treatment options, treatment directed
at GPER in these patients could be an effective therapeutic option. In order to
someday target this receptor in cancer, the mechanisms by which GPER
contributes to E2-induced processes, specifically E2-induced proliferation need
to be determined.
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1.6 Hypothesis
E2 is required for normal mammary gland development, function and
proper morphology; however, it also is able to stimulate proliferation in breast
tumors (Anderson, 2002). Studies performed in ER null mice have shown that
ERα mediates E2-induced proliferation in the breast, and this directly correlates
to ductal elongation and mammary gland branching morphogenesis (Brisken and
O'Malley, 2010). The most recently identified estrogen receptor, GPER, has been
shown to contribute to E2-induced signaling in breast cancer cells (Filardo et al.,
2000; Quinn et al., 2009), and GPER expression in breast tumors has been
correlated with poor prognosis, increased tumor size and distant metastasis and
increased HER-2/neu expression in patients with breast cancer. Even though
there is increasing evidence that GPER contributes to both normal estrogen
biology in the mammary gland as well as in breast cancer, it is still unclear if
GPER is directly involved in E2-induced proliferation and morphogenesis in the
breast. Based on our current understanding of E2’s actions in the breast, and
GPER’s role as an estrogen receptor, we hypothesize that GPER contributes to
E2-induced proliferation and morphogenesis in the human breast.
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1.6.1 Specific Aims
AIM 1 Determine if GPER activation contributes to estrogen-induced
proliferation
1.1 Determine if GPER promotes proliferation in an immortalized, nontransformed human breast epithelial cell line, MCF10A
1.2 Elucidate the signaling pathway downstream of GPER activation
leading to proliferation in MCF10A cells
1.3 Determine if GPER activation promotes proliferation in normal human
breast tissue and breast tumor tissue
AIM 2 Determine if GPER contributes to estrogen-induced regulation of
mammary gland morphogenesis
2.1 Determine if E2 and G-1 regulate alveolar morphology in human
breast tissue
2.2 Determine if E2 and G-1 regulate mitotic spindle orientation in
MCF10A cells in vitro in a 3-D model of breast epithelial morphogenesis
2.3 Determine if E2 and G-1 alter junctional E-cadherin expression in
human breast tissue
AIM 3 Determine if GPER contributes to estrogen-induced regulation of
spermatogenesis in murine testes
3.1 Determine the effects of E2 and G-1 on testes wet weight
3.2 Determine the effects of E2 and G-1 on morphological regulation and
spermatogenesis within the epididymis of male mice
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1.7 Figure legends
Figure 1.1 Regulation of 17β-estradiol production by the hypothalamicpituitary-gonadal axis.
Gonadotrophin releasing hormone (GnRH) is released from the hypothalamus
which stimulates cells in the anterior pituitary to release luteinizing hormone (LH)
and follicle-stimulating hormone (FSH). LH and FSH act on cells in the ovary to
stimulate the multistep conversion of cholesterol to E2. E2 produced by the
ovaries inhibits the hypothalamus from releasing GnRH, creating a negative
feedback loop.
Figure 1.2 Conversion of cholesterol to 17β-estradiol occurs in the ovary.
Luteinizing hormone (LH) released from the hypothalamus drives the conversion
of cholesterol to progesterone to androstenedione in theca cells in the ovary.
Androstenedione enters neighboring granulosa cells in the ovary, where folliclestimulating hormone (FSH) released from the hypothalamus promotes its
conversion into testosterone. Finally, aromatase converts testosterone into 17βestradiol.
Figure 1.3 Estrogen activation of classical estrogen receptors ERα/β.
In the absence of ligand, classical ERs are localized primarily in the nucleus
(some localization in cytoplasm), where heat shock proteins (HSP) and
chaperones keep them in an inactive conformation. Binding of 17β-estradiol (E2)
to ERs causes a conformation change which leads to the dissociation of HSPs,
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dimerization of ERs and translocation of cytoplasmic receptors into the nucleus.
Activated ER dimers bind to estrogen response elements (EREs) located within
the

promoter

region

of

estrogen-regulated

genes

and

modulate

their

transcription, thus mediating genomic estrogen signaling.
Figure 1.4 GPER-dependent signaling.
17β-estradiol (E2) is able to pass through the membrane and bind intracellular
GPER (GPR30) located on the endoplasmic reticulum. Upon E2 binding, GPER
is activated along with its associated heterotrimeric G proteins, which in turn can
activate the non-receptor tyrosine kinase Src. Activated Src can activate matrix
metalloproteases (MMPs) at the cell surface which leads to the cleavage of
heparin bound EGF (HB-EGF) growth actors from the cell membrane, allowing
pro-HB-EGF to bind to and activate the epidermal growth factor receptor (EGFR).
Activation of the EGFR leads to downstream activation of the MAPK and PI3K
pathways which promote proliferation and pro-survival signaling respectively.
Figure 1.5 GPER-selective Compounds.
Chemical structures of 17β-estradiol (E2; A), GPER-selective agonist G-1 (B),
and GPER-selective antagonist G-36 (C).
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1.8 Figures
Figure 1.1 Regulation of 17β-estradiol production by the hypothalamic-pituitary-gonadal
axis
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Figure 1.2 Conversion of cholesterol to 17β-estradiol occurs in the ovary
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Figure 1.3 Estrogen activation of classical estrogen receptors ERα/β
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Figure 1.4 GPER-dependent signaling
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Figure 1.5 GPER Selective Compounds
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2. Estrogen-induced activation of GPER and downstream
proliferative signaling
2.1 Abstract
Estrogen (17β-estradiol, E2) signaling is required to promote continued
development of the mammary gland at puberty. Importantly, E2 stimulates cell
proliferation in the mammary gland, which leads to ductal elongation and
regulation of breast morphology. In addition to a developmental setting, estrogen
promotes proliferation in a tumorigenic setting, which is of the ways by which
estrogen promotes breast cancer. The proliferative effects of E2 in the breast
have long been attributed to the two classical estrogen receptors, estrogen
receptor alpha (ERα) and estrogen receptor beta (ERβ); however, the effects of a
novel estrogen receptor, GPER, on breast epithelial proliferation remain unclear.
We hypothesize that GPER contributes to E2-induced proliferation in the breast.
In order to elucidate the effects of GPER activation on proliferation in the breast,
we used a non-transformed breast epithelial cell line, MCF10A, as well as an
organ culture model of human breast tissue. Activation of GPER by E2 and G-1
in human breast tissue led to a significant increase in proliferation measured by
Ki-67 staining. GPER activation also led to a significant increase in proliferation
in a breast epithelial cell line, MCF10A. We demonstrated, by western blot
analysis and inhibition of signaling components, that E2- and G-1-induced
proliferation in MCF10A cells is dependent on SRC, EGFR transactivation via
activation by HB-EGF and ERK activation; however it is not dependent on MMP
cleavage of HB-EGF at the cell surface. The specificity of GPER in E2-induced
proliferation was confirmed by the ability of G36 to abrogate E2 and G-1-induced
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proliferation in breast tissue and MCF10As as well as the ability of siRNA
knockdown of GPER to prevent E2- and G-1-induced proliferation in MCF10A
cells. The results of this study are the first demonstration of GPER-dependent
proliferation in human tissue, and emphasize the contributing role of GPER in
E2-induced breast proliferation.

26

2.2 Introduction
Normal growth and differentiation of the breast are under tight endocrine
control. This is demonstrated by the fact that mammary gland development is not
completed until the gland is exposed to circulating E2 at puberty, yet not in the
absence of E2 (Couse and Korach, 1999). E2’s actions in the breast are best
characterized as occurring through genomic signaling by activation of ligand
dependent transcription factors, including estrogen receptor alpha (ERα) and
estrogen receptor beta (ERβ) (Jensen and DeSombre, 1973; Kuiper et al., 1996).
In the breast, E2 acts through ER

to promote proliferation of the epithelium in

the developing gland at puberty, and consequently promotes ductal elongation
and outgrowth (Brisken and O'Malley, 2010). ERβ appears dispensable for
mammary gland growth and development in murine models (Korach et al., 1994),
but is instead responsible for terminal differentiation of the mammary gland in
preparation for lactation (Forster et al., 2002).
E2 induces breast epithelial proliferation through an autocrine mechanism,
in which E2 activation of ERα causes these cells to release amphiregulin, which
binds and activates its receptor on neighboring ER negative cells, leading to
activation of proliferation pathways (Willmarth and Ethier, 2006). In this manner,
cells that are ERα positive are distinct from those that are positive for proliferation
markers such as Ki-67 (Nelson and Bulun, 2001). There is extensive evidence
demonstrating E2’s ability to promote proliferation in vitro in human mammary
epithelial cells and breast cancer cells (Tan et al., 2009; Willmarth and Ethier,
2006a). E2 has also been shown to promote proliferation within the mammary
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epithelium of human breast tissue cultured ex vivo (Eigeliene et al., 2006);
exhibiting the proliferative role of E2 in a much more physiologically relevant
model.
Although E2 is required for normal breast development, its ability to
promote breast cancer is also well documented, making it a significant factor in
assessing breast cancer risk. In a tumorigenic setting, the autocrine regulation of
epithelial proliferation is lost, and proliferation positive cells are also positive for
estrogen receptors (McBryan et al., 2008; Tan et al., 2009; Willmarth and Ethier,
2006). For these reasons it is critical to have a complete understanding of E2’s
mechanisms of action mediated through specific receptors in the breast.
More recently it has become evident that, in addition to genomic signaling,
E2 can modulate rapid cellular signaling through the classical estrogen receptors
(Razandi et al., 2003). There is evidence that ERs can initiate extra-nuclear
signaling cascade complexes at the plasma membrane, often termed the
signalsome (Levin, 2002). These signaling cascades recruit second messengers
calcium and nitric oxide, receptor tyrosine kinases including the epidermal growth
factor receptor (EGFR), insulin-like growth factor (IGF-1R), various G proteincoupled receptors (GPCRs) and protein kinases including phosphoinositide-3
kinase (PI3K), serine-threonine kinase Akt, mitogen-activated protein kinase
(MAPK), nonreceptor tyrosine kinase Src, and protein kinases A and C (Levin,
2003).
Rapid E2-dependent signaling has also recently been demonstrated to
occur through the novel G protein-coupled estrogen receptor, GPER (Filardo and
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Thomas, 2005; Revankar et al., 2005), originally designated GPR30. E2
activation of GPER leads to transactivation of the EGFR and downstream
activation of MAP kinase and PI3 kinase signaling cascades in breast cancer
cells (Filardo et al., 2000). GPER expression has been observed in normal breast
tissue and breast tumors and in a large study performed in 2006, GPER
overexpression was correlated with an increased tumor size, distant metastasis
and HER-2/neu expression (Filardo et al., 2006); suggesting GPER expression is
a predictor of a more aggressive form of breast cancer. While Filardo and
colleagues observed significant correlations between tumor size, HER-2/neu
expression and GPER expression, confounding results have been presented
since. Two independent studies carried out more recently weren’t able to show a
significant association between GPER expression and HER-2/neu status and
although GPER positive tumors tended to be larger, the correlation was not
significant (Kuo et al., 2007; Luo et al., 2011). There has also been a study
assessing GPER expression and tumor progression variables in inflammatory
breast cancer, where it was observed that co-expression of ERα and GPER was
correlated with increased overall survival, and the absence of both ERα and
GPER in inflammatory breast tumors was correlated with decreased overall
survival (Arias-Pulido et al., 2010)
Observations of these studies complicate hypotheses of E2-induced
regulation of breast cancer, highlighting the urgency in determining GPERs
contribution to E2-induced processes in the breast. A contributing factor for the
aggressive phenotype correlating with GPER expression may be epithelial
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proliferation enhanced by GPER, given that this receptor has been previously
shown to contribute to E2-induced proliferation in vitro in breast cancer cell
lines,(Pandey et al., 2009; Vivacqua et al., 2006a; Vivacqua et al., 2006b) and in
vivo in the murine endometrium (Dennis et al., 2009). The aim of the present
study is to determine if GPER contributes to E2-induced epithelial proliferation in
the phenotypically normal human breast. Based on the fact that 1) E2 promotes
proliferation in hormone responsive tissue; 2) GPER promotes proliferation in
breast and other cell lines and tissue, and 3) GPER expression correlates with
breast cancer progression, we hypothesize GPER activation is responsible in
part for E2-induced proliferation in the human breast.
As E2 is able to activate ERα, ERβ and GPER, in order to discriminate the
roles of these individual receptors in proliferation, we have recently identified
reagents with specificity toward GPER, including a GPER-selective agonist, G-1
(Bologa et al., 2006), and a GPER-selective antagonist, G36 (Dennis et al.,
2009). In the present study we demonstrate that GPER is expressed in MCF10A
cells, that express no ER

or ER

(Debnath et al., 2003), and both E2 and

GPER agonist G-1are able to stimulate proliferation in these cells. The E2induced proliferation we observe in MCF10A cells is dependent on EGFR
transactivation via soluble HB-EGF and subsequent activation of ERK; however,
not dependent on activation of MMPs, a mechanism previously described
(Filardo et al., 2000). Proliferation is also induced in human breast tissue
explants in response to E2 and G-1, and we demonstrate that the proliferation is
in part mediated by GPER, as the GPER-selective antagonist G36 partially
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abrogates this effect. These results indicate that GPER contributes to E2-induced
proliferation in the breast, and is the first demonstration of GPER-mediated
proliferation in human tissue.

2.3 Results
2.3.1 Estrogen induces proliferation in MCF10A cells
MCF10A cells have been used extensively to study breast morphology in
vitro because of their ability to recapitulate breast epithelial morphogenesis when
cultured three dimensionally (3-D) on a reconstituted basement membrane
(Debnath et al., 2003). Due to the fact that these cells are ERα and ERβ
negative, they are not typically used in studies of E2- responsiveness, although
we had seen GPER expression in normal breast tissue (unpublished) and
wanted to investigate is this receptor was mediating E2 function in ER negative
breast epithelial cells. To determine if MCF10A cells proliferate upon E2
stimulation, cells were cultured in the presence of either vehicle (sham) or E2,
fixed and immunolabeled with an antibody that recognizes a mitosis-specific
phosphorylated form of Histone H3 (ser10),(pH3), a component of the
nucleosome. Following incubation of MCF10A cells for 24 hr with E2, we
observed a dose dependent increase in proliferation compared to control treated
cells; up to a 3-fold increase in cells treated with 100nM E2 (Fig 2.1).

2.3.2 MCF10A cells express GPER
Since we observed MCF10A cells to be E2 responsive, and they are
reported to lack ERα and ER , we reasoned that they likely express GPER, as
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the mediator of the E2-induced proliferative response. MCF10A cells
demonstrated GPER expression as determined by both immunofluorescence
staining and western blotting using a polyclonal antibody generated against a Cterminal peptide in the human GPER protein (Fig 2.2). Immunofluorescence
staining revealed an intracellular pattern for GPER in MCF10A cells, consistent
with an endoplasmic reticulum localization as described (Revankar et al.,
Science paper) (Fig 2.2A), that decreased considerably in intensity upon
transfection with a GPER-specific siRNA (GPER siRNA), but not with transfection
of non-specific, control siRNA (data not shown). Western immunoblotting using
the anti-GPER antibody demonstrated the presence of a specific polypeptide in
MCF10A cells (MW ~55kDa) (Fig 2.2B). This polypeptide was significantly
diminished in cells transfected with GPER siRNA (Figs 2.2B, 2.2C). The
polypeptide also decreased in intensity when the GPER specific antibody was
pre-incubated with the antigenic peptide, but not after pre-incubation with a
scrambled peptide (data not shown), confirming specificity of this antibody for
GPER. An additional polypeptide of lower molecular weight (~45kDa) was also
reduced by GPER siRNA (Fig 2.2B), suggesting the presence of GPER-specific
degradation products or isoforms. The absence of ERα mRNA and ERα protein
expression was confirmed in MCF10A cells by RT-PCR and immunofluorescence
(data not shown).

2.3.3 Estrogen-induced proliferation is mediated by GPER in MCF10A cells
Based on the observations that GPER is expressed in MCF10A cells, and
these cells exhibit increased proliferation in response to E2 stimulation, we
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further evaluated the effect of GPER-selective agonist G-1 and GPER-selective
antagonist G36 on proliferation in MCF10A cells. Cells stimulated with G-1 for 24
hours exhibited a dose-dependent increase in proliferation, up to a 3-fold
increase at the highest dose (100nM) compared to control treated cells (Fig
2.3A). To establish that the increased proliferation was due to GPER activation,
co-stimulation with agonists (E2 and G-1) and GPER-selective antagonist (G36)
were carried out and pH3 immunodetection was used to quantitate proliferation.
G36 significantly blocked both E2- and G-1-induced proliferation, but had no
effect on EGF-induced proliferation (Fig 2.3B). To further demonstrate that the
increased proliferation observed with E2 and G-1 treatment is due to activation of
GPER, proliferation was assessed in GPER-specific siRNA-transfected cells
(GPER siRNA) compared with non-specific siRNA-transfected cells. Cells in
which GPER protein expression was knocked down by GPER siRNA exhibited
significantly lower E2 and G-1 induced proliferation indexes as compared with
control siRNA-transfected cells (Fig 2.3C). GPER siRNA transfection had no
effect on EGF-induced proliferation in MCF10A cells (Fig 2.3C). Knockdown of
GPER protein expression in MCF10A cells was confirmed by Western
immunoblotting (Fig 2.3D).

2.3.4 E2 and G-1 induce ERK activation in MCF10A cells
As GPER is known to activate ERK (phosphorylation), and ERK activation
is upstream of cellular proliferation (Zhang and Liu, 2002) we reasoned that
GPER activation in MCF10A cells would result in ERK phosphorylation. Western
immunoblotting of E2- and G-1- treated MCF10A cell lysates was performed with
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an antibody against phosphorylated ERK (p-ERK). In preliminary experiments,
we determined that E2 and G-1 resulted in a time-dependent increase in p-ERK
as determined by band intensity relative to the loading control actin (data not
shown) with peak activation occurring at 15 minutes. Therefore all subsequent
stimulation experiments were terminated at 15 min. E2 and G-1 led to a
significant increase in the phosphorylation of ERK when compared to control
treated cells (Fig 2.4A), and treatment of cells with E2 or G-1 in combination with
GPER-selective

antagonist

G36

reduced

E2-

and

G-1-induced

ERK

phosphorylation significantly, while G36 alone had no effect. To more directly
attribute the observed ERK activation to GPER, ERK activation following E2 or
G-1 stimulation was assessed in cells that had been transfected with GPER
siRNA or control siRNA. MCF10A cells transfected with GPER siRNA exhibited
significantly lower E2- and G-1-induced ERK phosphorylation when compared to
control siRNA transfected MCF10A cells (Fig 2.4B). GPER siRNA knockdown
had no effect on EGF-induced ERK phosphorylation compared to control siRNAtransfected cells, demonstrating the specificity of the effects of GPER protein
knockdown (Fig 2.4B).

2.3.5 Mechanism of E2- and G-1-induced ERK activation in MCF10A cells
The mechanism of E2- and G-1-induced GPER-dependent ERK
phosphorylation was explored using pharmacologic signaling inhibitors. Since
GPER is known to transactivate the EGFR in breast cancer cell lines (Filardo et
al., 2000), we tested the ability of the EGFR-specific tyrosine kinase inhibitor,
AG1478, to block E2- and G-1-induced ERK phosphorylation in MCF10A cells
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(Fig. 2.5A). In addition, we also tested the MAPK Kinase (ERK) inhibitor, U0126
(Fig 2.5B) and the non-receptor tyrosine kinase SRC inhibitor, PP2 (Fig 2.5C) on
their ability to block E2- and G-1-induced ERK phosphorylation in MCF10A cells.
Pretreatment with AG1478 or U0126 prior to stimulation with GPER agonists
significantly blocked E2- and G-1-induced ERK phosphorylation (Figs 2.5A,
2.5B), demonstrating that EGFR activation is a consequence of E2- and G-1induced GPER activation in MCF10A cells. It has been shown previously that the
non-receptor tyrosine kinase Src is activated downstream of GPCR activation in
cancer cell lines (Frame, 2002), and there is evidence that Src can directly
activate the intracellular domain of the EGFR (Migliaccio et al., 2006). Based on
these observations, we sought to determine whether the Src inhibitor, PP2, could
block E2- and G-1-induced ERK phosphorylation downstream of GPER
activation in MCF10A cells. In cells pretreated with PP2, E2- and G-1-induced
ERK phosphorylation was significantly blocked when compared with cells
pretreated with Sham (Fig 2.5C); however, PP2 did not affect EGF-induced ERK
phosphorylation in cells (Fig 2.5C).
These results demonstrate that Src is upstream of EGFR transactivation in
MCF10A cells; however the direct mechanism by which Src activates EGFR in
MCF10A cells is still unidentified. It has been reported in breast cancer cells,
downstream of GPER, activated Src is able to activate MMPs at the cell surface
to cleave pro-HB-EGF, allowing the soluble ligand to bind EGFR (Filardo et al.,
2000) thus providing a distinct, extracellular mechanism for activation of EGFR
by Src. In order to determine if this is occurring in MCF10A cells, or if Src is able
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to activate the EGFR directly and intracellularly in MCF10A cells, we tested the
ability a broad spectrum MMP inhibitor, GM6001 (also reported to inhibit ADAMs
(Moss et al., 2007)), to block E2- and G-1-induced ERK phosphorylation.
GM6001 had no effect on E2- and G-1-induced ERK phosphorylation in MCF10A
cells when compared to cells pretreated with Sham (Fig 2.5D). The ability of
GM6001 to inhibit MMPs was verified by gel zymography (data not shown). Our
observations thus far indicate that Src can be activated in a GPER-dependent
fashion and is required for EGFR transactivation downstream of GPER in
MCF10A cells, although activation of MMPs are not required for E2- and G-1induced ERK phosphorylation in MCF10A cells.
These results suggest that Src is activating EGFR directly; however, to
determine the mechanism of EGFR transactivation downstream of Src activation,
we utilized two reagents; a diphtheria toxin mutant, CRM-197 that sequesters or
down-modulates surface-expressed pro-HB-EGF, inhibiting its mitogenic activity
(Naglich et al., 1992), and an antibody specific for HB-EGF that neutralizes and
blocks its ability to bind EGFR. Pro-HB-EGF is known to serve as the primary
binding site for diphtheria toxin (Naglich et al., 1992), and the mutant form of
diphtheria toxin, CRM-197, is able to bind pro-HB-EGF and sequester it,
preventing its signaling ability. To test the hypothesis that GPER is
transactivating the EGFR via HB-EGF, we measured ERK activation in MCF10A
cells that had been pretreated with either CRM-197 or an HB-EGF neutralizing
antibody prior to stimulation with E2 or G-1. Both CRM-197 and the HB-EGF
neutralizing

antibody

were

able

to
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block

E2-

and

G-1-induced

ERK

phosphorylation compared to cells pretreated with vehicle, but had no effect on
the ability of exogenous EGF to promote ERK phosphorylation (Fig 2.5E, 2.5F).

2.3.6 Mechanism of E2- and G-1-induced proliferation in MCF10A cells
In MCF10A cells, removal of exogenous EGF is sufficient to arrest cells in
G1 of the cell cycle, yet does not promote apoptosis (Chou et al., 1999),
therefore we sought to determine the effects of signaling inhibitors on E2- and G1-induced proliferation in MCF10A cells and to determine if E2 and G-1 sufficient
to promote proliferation in the absence of exogenous EGF. We first tested the
EGFR inhibitor, AG1478, the MAPK Kinase (ERK) inhibitor, U0126, and the PI3
Kinase inhibitor, LY294002, for their ability to block E2- and G-1-induced
proliferation in MCF10A cells. AG1478 completely blocked EGF-, E2- and G-1induced proliferation in MCF10A cells (Fig 26A). MAPK Kinase inhibitor, U0126,
also blocked E2- and G-1 induced ERK activation (Fig 2.6A); however,
pretreatment of MCF10A cells with PI3Kinase inhibitor LY294002 had no effect
on E2- and G-1-induced proliferation (Fig 2.6A), suggesting E2-and G-1-induced
proliferation occurs independently of PI3Kinase activation. We also tested the
ability of inhibitors of Src (PP2), MMP (GM6001), HB-EGF (CRM-197), and
EGFR ligand binding (HB-EGF neutralizing antibody) to block E2- and G-1induced proliferation. Pretreatment of MCF10A cells with PP2, CRM-197 or HBEGF neutralizing antibody blocked E2- and G-1-induced proliferation compared
to cells pretreated with vehicle (Fig 2.6B); however, none of these compounds
inhibited exogenous EGF-dependent proliferation (Fig 2.6B). GM6001 had no
effect on E2- and G-1-induced proliferation, similar to the non-effect of GM6001
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on E2- and G-1-induced ERK phosphorylation (Fig 2.6B), suggesting that
although Src is being activated downstream of GPER, MMP activation is not
required for E2- and G-1-induced proliferation in MCF10A cells.

2.3.7 E2 and G-1 induce proliferation in a 3-D model of breast morphogenesis
Our observations thus far indicate that activation of GPER via E2 or G-1
leads to a significant increase in proliferation in MCF10A cells in monolayer
culture (Fig 2.1, 2.3A, 2.3B), and this proliferation is dependent on the
transactivation of the EGFR and subsequent phosphorylation of ERK (Fig 2.6).
MCF10A cells are able to mimic breast epithelial morphogenesis when grown in
Matrigel™ (Debnath et al., 2003). When seeded as single cells, MCF10A cells
proliferate to form multicellular, hollow spheroids (Fig 2.7) similar to alveolar
structures found in the human breast in vivo, making them a more physiologically
relevant model to study proliferation. In the MCF10A 3-D model, cells are subject
to proliferation regulation by the surrounding basement membrane, and follow a
very ordered, reproducible timeline of events, making it a good model to study
mitogenic stimulation of proliferation. We sought to determine if E2- and G-1
could induce proliferation in MCF10A cells in 3-D; in a setting that is governed by
growth controls from the surrounding microenvironment, i.e. Matrigel™ (Debnath
et al., 2003). Proliferation was detected in MCF10A cells stimulated in Matrigel™
for six days (treatments began on day four post-seeding and cells were fixed on
day ten) by immunodetection of proliferation marker p-H3 (Fig 2.8A; green).
Cells were co-labeled with an antibody raised against α-tubulin (Fig 2.8A; red),
and nuclei are stained with Topro-3 (Fig 2.8A; blue). E2- and G-1 both induce a
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significant increase in proliferation in MCF10A cells in 3-D after six days of
treatment compared to control-treated cells (Fig 2.8B). E2- and G-1 treatment
also led to an increase in cell number per spheroid (Fig 2.8C), indicating that E2
and G-1 stimulation lead to cell cycle completion in MCF10A cells.

2.3.8 GPER contributes to E2-induced proliferation in human breast tissue
Since GPER activation was able to mediate proliferation in nontumorigenic MCF10A cells, we sought to determine if E2-dependent proliferation
in human breast tissue, cultured as described (Eigeliene et al., 2006; Fig 2.9),
was mediated in part by GPER. We confirmed expression of estrogen receptors
in

human

breast

tissue

explants

by

immunohistochemical

analysis

(immunohistochemistry; IHC) using antibodies against GPER (Fig 2.10C) or ERα
(Fig 2.10D). While ERα alpha expression and staining intensity was uniform
throughout breast tissue samples, GPER staining intensity was more variable,
although every sample in which proliferation was assessed was GPER positive,
based on IHC.
Immunodetection of proliferation marker Ki-67 was used to elucidate the
effect of GPER activation on proliferation in mammary explants after seven days
in culture. Ki-67 proliferation marker was used to quantitate proliferation in breast
tissue instead of pH3, since Ki-67 is a much broader proliferation marker,
labeling all cells in the cell cycle, whereas pH3 only labels cells in mitosis. Due to
the proliferation rates in breast tissue being much lower than that in MCF10A
cells, we used Ki-67 immunostaining to capture a larger percentage of
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proliferating cells. Treatment of breast tissue explants with E2 or G-1 significantly
increased epithelial cell proliferation, compared to control (Fig 2.10A). Breast
tissue explants treated with GPER antagonist G36 alone had no effect (Fig
2.10B); however, G36 significantly reduced E2- and G-1-dependent proliferation,
suggesting that GPER contributes to E2-induced proliferation in primary human
breast tissues.

2.3.9 E2 and G-1 promote proliferation in tumorigenic human breast tissue
In addition to investigating GPER’s contribution to E2-induced proliferation
in normal human breast tissue, we also were interested if E2 or G-1 were able to
promote proliferation (measured by Ki-67 immunostaining) in human breast
tumor tissue after seven days of stimulation. Treatment of breast tumor tissue
explants with E2 or G-1 significantly increased epithelial cell proliferation,
compared to control (Fig. 2.11). Whereas explants treated with GPER antagonist
G36 alone had no effect, G36 was able to significantly reduced E2- and G-1dependent proliferation (Fig. 2.11), suggesting that GPER activation contributes
to E2-induced proliferation in primary breast tumor tissue, similar to the effect of
E2 and G-1 on non-tumorigenic breast tissue.
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2.4 Discussion
The proliferative effects of E2 in the breast are well established and have long
been attributed to the classical estrogen receptors ERα and ERβ (Brisken and
O'Malley, 2010). However, it is not known if the novel G-protein-coupled estrogen
receptor, GPER, can promote E2-induced proliferation in the normal human
breast. It was demonstrated that GPER can mediate proliferation in SKBr3 breast
cancer cells (Pandey et al, 2009), endometrial cancer cells (Vivacqua et al.,
2006b), and ovarian cancer cells (Albanito et al., 2007); however, there is also
evidence that GPER inhibits proliferation of ER positive MCF7 breast cancer
cells (Ariazi et al., 2010). Moreover, our group has shown that GPER promotes
proliferation in vivo, in the murine endometrium (Dennis et al., 2009). Due to the
ability of GPER to both promote and inhibit proliferation depending on cell type
and estrogen receptor status, we were interested in the role of GPER in E2induced proliferation in the normal human breast. We addressed this question by
directly measuring GPER-dependent proliferation in a human breast epithelial
cell line, MCF10A, and in human breast tissue. We showed that E2 and the
GPER-selective agonist G-1 induce proliferation in MCF10A cells both in
standard monolayer culture (Fig 2.1), and in a 3-D model of breast epithelial
morphogenesis, where growth control cues are present (Fig 2.8). These cells
express GPER but not ERα and ERβ (Fig 2.2), suggesting that E2-induced
proliferation is dependent on GPER alone in MCF10A cells. To support the role
of GPER in E2-induced proliferation, we used a GPER-selective antagonist, G36,
as well as GPER-targeted siRNA in proliferation assays. Both treatments blocked
E2- and G-1-induced proliferation (Fig 2.3B, C).
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Our results also demonstrate that E2 promotes proliferation in normal
human breast tissue explants from reduction mammoplasty surgery (Fig 2.10A),
consistent with previous findings (Eigeliene et al., 2006). GPER-selective agonist
G-1 also promoted proliferation in human breast tissue explant cultures
compared to control treated tissue, albeit at a reduced level compared to E2 (Fig
2.10B). Moreover, G36 completely blocked G-1-induced proliferation (Fig 2.10B).
G36 also partially blocked E2-induced proliferation in human breast tissue
explants, suggesting that E2–dependent proliferation in the human breast occurs
through activation of multiple estrogen receptors, including GPER. Therefore this
study is the first to demonstrate GPER-dependent proliferation in a normal
human tissue.
Filardo and colleagues previously demonstrated that E2-dependent GPER
activation leads to EGFR transactivation, with subsequent Erk-1 and Erk-2
activation in breast cancer cells (Filardo et al., 2000). GPER transactivation of
the EGFR and subsequent activation of downstream signaling pathways is
consistent with our prior observation that E2-dependent GPER activation
stimulates the PI3K pathway, in an EGFR activation-dependent manner
(Revankar et al., 2005). Therefore, in order to dissect the molecular pathway by
which GPER promotes proliferation in a normal, non-tumorigenic setting, we
targeted different components of the EGFR/MAPK signaling pathway (Filardo et
al., 2000; Quinn et al., 2009). Our results reveal that E2- and G-1-induced GPER
activation of leads to EGFR transactivation and subsequent ERK activation (Fig
2.4). Moreover, EGFR transactivation and subsequent ERK activation is required
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for E2- and G-1-induced proliferation in MCF10A cells (Fig 2.6). PI3Kinase
inhibitor LY294002 had no effect on E2- and G-1-induced proliferation,
suggesting activation of the MAPK signaling pathway downstream of EGFR
transactivation is independent of PI3Kinase activation. We also determined that
in MCF10A cells, although activation of the non-receptor tyrosine kinase Src is
required for GPER-dependent activation of ERK and proliferation, MMP activity is
not required for EGFR transactivation (measured by ERK activation) (Fig 2.5D)
or proliferation (Fig 2.5B). Nevertheless, we confirmed the requirement for HBEGF to promote E2- and G-1-induced phosphorylation of ERK and proliferation
downstream of GPER activation, because sequestering and down-modulating
pro-HB-EGF with CRM-197 or blocking its ability to bind EGFR with neutralizing
antibodies abolished GPER-dependent ERK activation and proliferation (Fig
2.5E,F, 2.6B). It has been reported that membrane tethered pro-HB-EGF can
activate the EGFR on adjacent cells in a juxtacrine manner, independent of
cleavage by proteases (Dong et al., 2005; Takemura et al., 1997). Pro-HB-EGF
signaling has been previously reported in MCF10A cells (Willmarth and Ethier,
2006a), and it is possible this is the mechanism of transactivation of the EGFR
downstream of GPER activation in these cells.
In this study, we show for the first time that GPER mediates E2-induced
proliferation in normal breast tissue and in normal human tumor tissue. We have
also demonstrated a novel mechanism for transactivation of the EGFR in
MCF10A cells downstream of GPER. Given the ability of GPER to promote
proliferation in normal breast tissue as well as breast cancer cells, and the
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correlation between GPER expression and negative outcome in a breast tumor
setting, the need to understand the mechanism of E2-induced proliferation and
signaling is essential. The demonstrated ability of GPER-selective antagonist
G36 to block E2-induced proliferation in vitro in cell lines (Fig 2.3) as well as in
human tissue highlights its potential importance in therapeutic intervention in
breast and other E2-responsive tissues
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2.5 Materials and Methods
2.5.1 Reagents
Dulbecco’s Modified Eagle Medium (DMEM), phenol red-free DMEM, E2,
fetal bovine serum (FBS), normal goat serum (NGS), insulin, cholera toxin,
transferrin, hydrocortisone and prolactin were from Sigma (St. Louis, MO).
Recombinant epidermal growth factor (EGF) and penicillin/streptomycin (P/S)
were from Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA) was from
Amresco (Solon, OH). Growth factor reduced phenol red-free Matrigel™ was
from BD Biosciences (San Jose, CA). G-1 was synthesized as described (Bologa
et al., 2006) and provided by Jeffrey Arterburn (New Mexico State University, Las
Cruces, NM). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA). Small
interfering RNA (siRNA) was purchased from Dharmacon RNAi Technologies
(Dharmacon, Lafayette, CO): ON-TARGET plus SMARTpool siRNA for GPER (L005563-00) and ON-TARGETplus siControl Non-Targeting siRNA (D-00181002).

2.5.2 Inhibitors and antibodies
EGFR inhibitor Tyrphostin AG1478, PI3K inhibitor LY294002, Src inhibitor
PP2, MEK inhibitor U0126 and MMP inhibitor GM6001 were from Calbiochem
(La Jolla, CA). Diphtheria toxin mutant CRM-197 (Berna Products, Coral Gables,
FL) and HB-EGF neutralizing antibody (R&D Systems, Minneapolis, MN) were a
gift from Edward Filardo (Brown University, Providence, RI). G36 was
synthesized as described (Dennis et al., 2011) and provided by Jeffrey Arterburn
(New Mexico State University). Polyclonal antibody against the human GPER (c45

terminus) was used for GPER localization assays. Rabbit p-Histone H3 antibody
and mouse β-actin antibody were from Millipore (Billerica, MA). Rabbit
antiphospho-p-44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody was from Cell
Signaling (Beverly, MA). Rabbit anti-Ki-67 antibody was from Neomarkers/Lab
Vision (Thermo Fisher, Kalamazoo, MI). Mouse anti-α-tubulin antibody was from
Sigma (St. Louis, MO). Goat antirabbit IgG-Alexa 488-conjugated secondary
antibody and Goat antimouse IgG-Alexa 533-conjugated secondary antibody
were from Invitrogen (Carlsbad, CA). Goat antirabbit IgG-HRP-conjugated
antibody was from GE Healthcare (Princeton, NJ) and goat antimouse IgG-HRPconjugated antibody was from Cell Signaling.

2.5.3 Cell Culture
Immortalized, non transformed MCF10A human breast epithelial cells
(ATCC, Manassas, VA; catalog number CRL-10317) were maintained in
MCF10A complete media (DMEM/F-12 supplemented with 5% dextran-charcoalstripped fetal bovine serum, 10 μg/mL insulin, 100 ng/mL cholera toxin, 0.5
μg/mL hydrocortisone, 20 ng/mL recombinant epidermal growth factor and 1%
penicillin/streptomycin). Cells were cultured in a humidified atmosphere
containing 5% CO2 at 37◦C. For proliferation assays, cells were passaged onto
12mm glass coverslips (Electron Microscopy Sciences, Hatfield, PA) and
cultured in phenol red-free MCF10A media with all supplements listed above.
Overnight cell synchronization for proliferation and immunoblot analysis was
performed as previously described (Chou et al., 1999). After overnight
synchronization, cells were stimulated for 24 hours with vehicle control, 17-beta
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estradiol (1nM to 100nM) (E2), G-1 (GPER-selective agonist) (1nM to 100nM),
and

G36

(GPER-selective

antagonist;

5nM

to

500nM),

fixed

in

4%

paraformaldehyde in phosphate-buffered saline (PBS) for 15 minutes at room
temperature. Compounds were diluted in dimethylsulfoxide (DMSO); therefore
control tissues were incubated in media supplemented with DMSO vehicle. For
some experiments, MCF10A cells were grown in 60mm cell culture dishes and
transfected with siRNA using Lipofectamine 2000 as per manufacturer’s
instructions. For immunoblot analysis, cells were grown on 60mm plates in
phenol red-free MCF10A media, synchronized overnight and stimulated with
compound.
MCF10A cells were also grown in Growth Factor Reduced phenol red-free
Matrigel™ on 8-well chamber slides (BD Falcon, San Jose, CA). Approximately
5,000 MCF10A cells were seeded on 40µL of Matrigel in each chamber on the
slide. Cells were suspended in growth media (described above) supplemented
with 2% Matrigel. The media was changed every two days, and after four days in
culture, various treatment compounds were added to growth media. Cells
continued to grow in Matrigel until day 10, whereby they were fixed with 4% PFA
in PBS for 15 minutes at room temperature. Immunofluoresence assays were
carried out of MCF10A cells in 2D and 3D according to a method previously
described (Debnath et al., 2003). Images were captured on either a Zeiss 200M
Axiovert inverted microscope (Carl Zeiss Inc., Oberkochen, Germany), using a
x400 total magnification (2-D cells) or a Zeiss LSM 510 confocal microscope
using x400 total magnification and an optical thickness of 0.7 µM (3-D cells).
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2.5.4 Tissue Samples
Human breast tissue was acquired from female patients who were
undergoing reduction mammoplasty surgery between November 2007 and
January 2011. Normal breast tissue remaining after pathological testing was
collected and used in this study. Successive specimens were collected at
University of New Mexico hospital (UNMH), and received from the cooperative
human tissue network (CHTN Western division- Vanderbilt University, Nashville,
TN), a division of the National Cancer Institute. This study protocol was approved
by University of New Mexico Health Sciences Center institutional review board
(IRB). Tissue collected at UNMH was transported to the laboratory on ice in DMEM/F-12 medium containing 1% P/S, within 1-2 hours of surgery. Tissue
obtained from CHTN was shipped overnight on ice in RPMI medium (Sigma)
supplemented with 1% P/S. The tissue was dissected into 3 mm3 pieces in
phenol-red free D-MEM/F-12 medium in order to exclude as much adipose
tissues as possible, saving the collagenous connective tissue where the epithelial
ducts and lobules are found.

2.5.5 Organ Culture
Breast tissue was incubated according to a previously described method
(Eigeliene et al., 2006), in which pieces of breast tissue are placed on sterile lens
paper lying on stainless steel grids (our protocol modified this to use nylon grids)
atop a 35mm tissue culture dishes inside a 10cm dish. For experiments done in
breast tumor tissue, tissue was submerged in media in a 24 well plate. Tissue
was incubated overnight in a humidified atmosphere with a mixture of 5% CO2
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and 95% air at 37˚C in phenol-red free D-MEM/F-12 medium supplemented with
1% P/S, 10ug/mL insulin, 3ug/mL prolactin, 4mg/ml transferrin and 1ug/mL
hydrocortisone. Following overnight incubation to ―rest‖ the tissue, additions were
made to the medium in the inner tissue culture dish; including vehicle control, 17beta estradiol (1nM to 100nM) (E2), G-1 (GPER-selective agonist) (1nM to
100nM), and G36 (GPER-selective antagonist; 5nM to 500nM). Compounds
were diluted in dimethylsulfoxide (DMSO); therefore control tissues were
incubated in media supplemented with DMSO vehicle. Growth media was
changed every two days and fresh treatments were added. Tissue was collected
7 days after the addition of treatments and fixed in 4% paraformaldehyde (PFA)
in phosphate buffered saline (PBS) overnight at room temperature.

2.5.6 Indirect Immunofluorescence (Tissue)
For immunofluorescence staining, paraffin sections (5µm) were mounted
on Super-Frost Plus slides (Menzel- Gläser, Germany). After rehydrating
sections through a graded alcohol series followed by water, the slides were
treated for antigen retrieval by boiling in a microwave oven in 0.01 M citrate
buffer (pH 6.0) for 20 minutes. After a series of washes the sections were
incubated with 0.1% Triton X-100 containing 3% NGS for 30 min at room
temperature to permeabilize cells and block non-specific binding antibody. Tissue
sections were then incubated with primary antibodies diluted in PBS + 0.1%
Tween-20 containing 3% NGS overnight at 4°C in a humid chamber. Following
overnight incubation with primary antibody, tissue sections were washed and
incubated with species-matched Alexafluor conjugated secondary antibodies
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(Invitrogen) for 1 hour at room temperature in a dark chamber. Sections were
incubated for 15 minutes with Topro-3 (Molecular Probes) to stain nuclei.
Sections were mounted with Vectashield mounting media (Vector Labs) and
sealed with nail polish. Images were captured on either a Zeiss 200M Axiovert
inverted microscope using a x400 total magnification or a Zeiss LSM 510
confocal microscope (Carl Zeiss Inc., Oberkochen, Germany), using x400 total
magnification and an optical thickness of 0.7 µm.

2.5.7 Western Immunoblotting
Cells were lysed in RIPA buffer supplemented with buffer supplemented
with

sodium

fluoride

(50

mM),

sodium

orthovanadate

(1

mM),

phenylmethylsulfonylfluoride (1 mM), and protease cocktail (1X). Cell lysate
protein concentration was determined by performing a Bradford protein assay
(Bio-rad, Hercules, CA). Equal protein concentrations per lysate were loaded on
a 4-20% SDS-PAGE gel (Thermo-Scientific, Rockford, IL) and then transferred to
polyvinylidene difluoride membranes (Millipore, Billerica, MA). After blocking in
5% nonfat dry milk for 1 hour at room temp, the membranes were incubated with
primary antibodies at a 1:100 to 1:10,000 dilution in 3% BSA overnight at 4˚C
with gentle rocking. After a series of washing, the blots were then incubated with
horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG
at 1:10,000 in 3% BSA for 1 hour at room temperature with gentle rocking. The
blots were developed using Supersignal West Pico Chemilumiscent Substrate
(Thermo Fisher). Films were then scanned and quantified using ImageJ software
(National Institutes of Health, Bethesda, MD)
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2.5.8 Quantitation
For Ki-67 and p-histone H3 immunofluorescence assays, cells staining
positive for these proliferation markers were expressed as a percentage of the
total number of cells in each treatment sample. Blind quantitation was performed,
and fields were chosen at random.

2.5.9 Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.03 (La
Jolla, CA). Analysis done with a one way analysis of variance (ANOVA) within
Prism estimates the correlation of variables (protein expression, proliferation, etc)
with treatment groups (sham, E2, G-1, G-36, etc). Pairwise comparisons of
results between different treatment groups were determined using a one-way
Analysis of Variance (ANOVA) followed by a Dunnett’s test. Data represents the
mean ± SEM of three or more separate experiments. P-values less than 0.05
were considered to be significant.
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2.6 Figure Legends
Figure 2.1 17-β Estradiol stimulates proliferation in MCF10A cells.
Proliferation was assessed by immunofluorescence using an anti-phospho
(ser10) Histone H3 (pH3) antibody in MCF10A cells cultured in the presence of
vehicle (sham) or the indicated concentrations of 17-β estradiol (E2) for 24 hours.
Data represents the average of three independent experiments. Results are
expressed as mean ± SEM and statistical significance (p ≤ .05) was assessed by
one-way ANOVA followed by a Dunnett’s test. (*, significantly different relative to
sham)
Figure 2.2 MCF10A cells express GPER.
GPER expression was assessed in MCF10A cells by immunofluorescence (A)
and western blotting (B), probing with an anti-human GPER peptide antibody.
siRNA knockdown of GPER expression was also demonstrated in cells
transfected

with

GPER-specific

siRNA,

72hours

following

transfection

(representative experiment shown in B). Cells transfected with non-specific
(scrambled) control siRNA express normal levels of protein (B). The histogram
displays densitometric quantitation of three independent GPER immunoblots
following no transfection (NT), or 72 hr following transfection with control siRNA
or

GPER-specific

siRNA

(C).

Quantitation

is

normalized

to

β-actin

immunodetection. Results are expressed as mean ± SEM and statistical
significance (p = .0176) was assessed by one-way ANOVA followed by a
Dunnett’s test. (*, statistically significant relative to non-transfected cells)
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Figure 2.3 E2 and G-1-induced proliferation is dependent on GPER in
MCF10A cells.
Proliferation was assessed in MCF10A cells grown on glass coverslips in the
presence of indicated concentrations of GPER agonists (E2, G-1) and antagonist
G36 for 24 hours (A, B). Proliferation was also assessed in control and GPER
siRNA transfected MCF10A cells following 24 hour stimulation with E2 or G-1
(C). Proliferation was quantified by immunofluorescence using an anti-phospho
Histone H3 antibody. Knockdown of GPER was confirmed by western blot with
anti-GPER antibody (D). Data is representative of a minimum of three
independent experiments. Results are expressed as mean ± SEM and statistical
significance (P≤ .05) was assessed by one-way ANOVA followed by a Dunnett’s
test. (*, significantly different relative to sham; #, significantly different relative to
E2 or G-1; ns = not significant.)
Figure 2.4 GPER activation induces activation of the MAPK signaling
cascade.
MCF10A cells were stimulated with indicated concentrations of E2 or G-1 alone
or in combination with GPER antagonist G36, for 15 minutes (A). Lysates were
prepared and immunoblotted with antibodies specific to phospho-ERK (p-ERK).
Equal protein loading was confirmed by β-actin immunoblotting. Histograms
represent fold change (p-ERK relative to actin) in p-ERK protein expression,
relative to vehicle-treated cells (sham). p-ERK was also assayed in cells
transfected with control or GPER siRNA-treated cells 72 hours after transfection,
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and then stimulated with E2 or G-1 for 15 minutes (B). Data are representative of
three independent experiments. Results are expressed as mean ± SEM and
statistical significance (P≤ .05) was assessed by one-way ANOVA followed by a
Dunnett’s test. (*, significantly different relative to sham; #, significantly different
relative to E2 or G-1)
Figure 2.5 GPER-dependent activation of MAPK (ERK1 and ERK2) is
dependent on Src activation but not MMP activation in MCF10A cells.
Signal transduction inhibitors were tested for their ability to block GPERdependent ERK activation in MCF10A cells. Cells were pre-incubated for 30
minutes with either vehicle (sham), AG1478 (A, 250 nM, inhibitor of EGFR),
U0126 (B, 10uM, inhibitor of MEK), PP2 (C, 10 nM, inhibitor of Src), GM6001 (D,
25 uM, inhibitor of MMPs), CRM-197 (E, 0.2mg/mL, inhibitor of HB-EGF or HBEGF neutralizing antibody (F, 6ng/mL), then stimulated with 10nM EGF, 10nM
E2 or 100nM G-1 for 15 minutes. Lysates were western blotted with antibodies
specific for phospho-ERK. Equal protein loading was confirmed by β-actin
immunoblotting. Histograms represent fold change in p-ERK protein expression.
Data are representative of three independent experiments. Results are
expressed as mean ± SEM and statistical significance (P≤ .05) was assessed by
one-way ANOVA followed by a Dunnett’s test. (* significantly different relative to
sham)
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Figure 2.6 GPER-dependent proliferation requires transactivation of the
EGFR.
Signal transduction inhibitors were tested for their ability to block GPERdependent proliferation in MCF10A cells. Cells were preincubated for 30 minutes
with either vehicle (sham, A & B), AG1478 (250nM, EGFR inhibitor, A), U0126
(10uM, MEK inhibitor, A), LY294002 (10uM, PI3K inhibitor, A), PP2 (10nM, Src
inhibitor, B), GM6001 (25uM, MMP inhibitor, B), CRM197 (HB-EGF release
inhibitor, (0.2mg.mL, B) or HB-EGF neutralizing antibody (6ng/mL, B) and then
stimulated with EGF (10 nM), E2 (10 nM) or G-1 (100 nM) for 24 hours.
Proliferation was quantified by immunofluorescence using an anti-phospho
Histone H3 antibody (pH3). Data are representative of a minimum of three
independent experiments. Results are expressed as mean ± SEM and statistical
significance (P≤ .05) was assessed by one-way ANOVA followed by a Dunnett’s
test. (* significantly different relative to sham).
Figure 2.7 Illustration of MCF10A 3-D culture method.
Figure taken from Debnath et al, 2003, Methods, 30; p 261
Figure 2.8 Estrogen-induced GPER activation stimulates proliferation in a
3-dimensional model of breast morphogenesis.
MCF10A cells were grown in 3D on Matrigel™ basement membrane in the
presence of 10nM E2 or 100nM G-1 for six days in culture. Proliferation (B) was
quantified by immunofluorescence using an anti-pH3 antibody. An representative
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spheroid immunolabeled with pH3 (green) and anti-gamma tubulin (ref) is shown
(A; arrow indicates phospho-histone immunolabeled chromatin; arrowhead
indicates mitotic spindle). Total cell number per spheroid was quantified for each
treatment group (C). Data are representative of three independent experiments.
Results are expressed as mean ± SEM and statistical significance (P≤ .05) was
assessed by one-way ANOVA followed by a Dunnett’s test. (*, significantly
different relative to sham).
Figure 2.9 Illustration of human breast tissue culture method.
Figure taken from Eigeliene et al, 2006, BMC Cancer 6; p 3
Figure 2.10 E2 and G-1 promote proliferation in human breast tissue.
Breast epithelial proliferation was assessed in the presence of GPER agonists
E2 and G-1(A, B) and antagonist G36 (B) in alveolar structures within human
breast tissue explants expressing both ERα (C) and GPER (D). Proliferation of
luminal epithelial cells was quantified by immunofluorescence using anti-Ki-67
antibody. ERα (C) and GPER (D) protein expression was confirmed by
immunohistochemistry analysis using antibodies directed at each protein. Each
treatment group consisted of tissue samples from a minimum of five different
patients. Results are expressed as mean ± SEM, and statistical significance (P ≤
0.05) was assessed by one way ANOVA followed by a Dunnett’s t-test. (*
significantly different relative to sham, # significantly different relative to E2 or G1)
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Figure 2.11 E2 and G-1 promote proliferation in tumorigenic human breast
tissue.
Breast tumor proliferation was assessed in the presence of GPER agonists E2
and

G-1

and

antagonist

G36.

Proliferation

was

quantified

by

immunofluorescence using anti-Ki-67 antibody. Each treatment group consisted
of tissue samples from a minimum of five different patients. Results are
expressed as mean ± SEM, and statistical significance (P ≤ 0.05) was assessed
by one way ANOVA followed by a Dunnett’s t-test. (* significantly different
relative to sham, # significantly different relative to E2 or G-1)

57

2.7 Figures
Figure 2.1 17-β Estradiol stimulates proliferation in MCF10A cells
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Figure 2.2 MCF10A cells express GPER
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Figure 2.3 E2 and G-1-induced proliferation is dependent on GPER in MCF10A cells
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Figure 2.3 E2 and G-1-induced proliferation is dependent on GPER in MCF10A cells
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Figure 2.4 GPER activation induces activation of the MAPK signaling cascade
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Figure 2.4 GPER activation induces activation of the MAPK signaling cascade
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Figure 2.5 GPER-dependent activation of MAPK (ERK1 and ERK2) is dependent on Src
activation but not MMP activation in MCF10A cells.
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Figure 2.5 GPER-dependent transactivation of the EGFR is dependent on Src activation
but not MMP activation in MCF10A cells.
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Figure 2.6 GPER-dependent proliferation requires transactivation of the EGFR.
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Figure 2.7 Illustration of MCF10A 3-D culture method
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Figure 2.8 Estrogen-induced GPER activation stimulates proliferation in a 3-dimensional
model of breast morphogenesis
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Figure 2.9 Illustration of human breast tissue culture method
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Figure 2.10 E2 and G-1 promote proliferation in human breast tissue
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Figure 2.10 E2 and G-1 promote proliferation in human breast tissue
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Figure 2.11 E2 and G-1 promote proliferation in tumorigenic human breast tissue
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3. ESTROGEN REGULATION OF CELL DIVISON ORIENTATION
AND ALVEOLAR MORPHOLOGY IN THE MAMMARY GLAND
3.1 Abstract
Estrogen (17β-estradiol, E2) is a potent mitogen, able to promote
proliferation and morphological homeostasis in the mammary gland. Classical
estrogen receptors (ERs) ERα and ERβ, are known to mediate the effects of E2induced morphogenesis in the mammary gland based on studies done with ER
null mice; however it is unknown if the novel G protein-coupled estrogen receptor
(GPER) mediates the effects E2 on breast epithelial morphogenesis. Since we
have previously shown that GPER mediates the proliferative effects of E2 in the
breast,

and

E2-induced

proliferation

promotes

ductal

elongation

and

morphological development of the mammary gland, we hypothesize that GPER is
mediating E2-induced morphogenesis in the breast. To determine the
involvement of GPER in E2-induced breast epithelial morphogenesis, we utilized
an ex vivo model to culture human breast tissue in the presence of E2, GPERselective agonist G-1 and GPER-selective antagonist G36. We also used a 3-D
cell culture model of MCF10A breast epithelial cells to answer questions of
morphology and regulation of mitotic spindle orientation.
We found that E2 and G-1 stimulation of human breast tissue for seven
days led to distinct morphological characteristics within alveolar structures in the
mammary gland. E2 led to an increase in luminal epithelial layers, and this effect
was not abrogated by G36, suggesting the E2-induced increase in epithelial
height is mediated by classical ERs and not GPER. G-1 stimulation of breast
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tissue resulted in an increase in the area of the lumen in alveolar structures
(luminal area). G36 was able to significantly reduce the increased luminal area
promoted by G-1 stimulation, suggesting this phenotype is mediated by GPER.
We also found that MCF10A 3-D spheroids treated with E2 exhibited
mitosis in which the mitotic spindle had been rotated to be perpendicular relative
to the basement membrane, whereas sham and G-1 treated mitotic MCF10A
cells retained mitotic spindle orientation parallel relative to the basement
membrane. We investigated E-cadherin expression in the human breast tissue,
since adhesion molecules are known to be important for guiding mitotic spindle
orientation during proliferation, and we found that E2 and G-1 have different
effects on E-cadherin expression. E2 stimulation of breast tissue, after seven
days increased E-cadherin expression whereas G-1 stimulation decreased Ecadherin expression at cell-cell junction in alveolar structures. We observed
increased FAK activation in G-1 treated MCF10A cells, and since FAK is a
known binding partner of Src and Src is activated downstream of GPER, it is
possible that FAK/Src phosphorylation of E-cadherin is leading to its
downregulation in human breast tissue. The relationship of E2, GPER and mitotic
spindle orientation is complex but our results do support a role for GPER in E2induced breast epithelial morphogenesis.
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3.2 Introduction
E2 regulates breast epithelial morphogenesis and maintenance of
mammary gland homeostasis. This has been shown through studies in estrogen
receptor knockout animals, where the mammary gland remains a rudimentary
structure due to the lack of ERα- induced proliferation and subsequent branching
morphogenesis, occurring during development (Brisken and O'Malley, 2010). E2
induces changes in human breast tissue cultured ex vivo after one week of
stimulation (Eigeliene et al., 2006), in which E2 treatment led to a multi-layered
luminal epithelium and increased luminal epithelial cell height, concomitant with
increased proliferation in ductal/alveolar structures in breast tissue; however
control-treated tissue maintained a single layer of luminal epithelial cells
(Eigeliene et al., 2006).
A possible mechanism influencing breast morphology is the orientation of
cell division. Cells divide in an orientation dependent upon the position of the
mitotic spindles, which occurs perpendicular to the final plane of division (Fig.
3.1). In the case of simple epithelia, mitotic spindle orientation relative to the
underlying basement membrane will determine whether cell division results in
two daughter cells lying parallel with or perpendicular to the basement
membrane. In order to maintain the single layer of epithelial cells, cell division
parallel to the basement membrane predominates (Perez-Moreno et al., 2003).
Loss of parallel cell division orientation, e.g., due to signals that promote rotation
in the mitotic spindle, would disrupt epithelial tissue morphology and allow for
vertical tissue expansion. Morphology such as this is observed in early breast
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cancers including Ductal Carcinoma In Situ (DCIS), where epithelial cells fill the
lumen, rather than maintaining simple cuboidal epithelial morphology. Other
factors, such as evasion of apoptosis in central-located cells, may also be playing
a crucial role in this type of dysmorphology; however, it is interesting that E2 is
reported to induce a rotation in the mitotic spindle apparatus (perpendicular to
the basement membrane) in hormone responsive tissues including the
endometrium (Gunin, 2001) and the prostate (Liu et al., 2008), suggesting this
could also occur in the mammary gland. Although mechanisms regulating the
mitotic spindle are still being elucidated, establishment of epithelial polarity and
the formation of cell-cell junctions and cell-ECM interactions seem to be
important determinants in mitotic spindle orientation (van Roy and Berx, 2008;
Wheelock and Johnson, 2003). Thus, factors such as junctional proteins,
specifically E-cadherin in adherens junctions between cells have the potential to
contribute to the generation of polarity cues that are important for orienting
mitotic spindles during cell division (den Elzen et al., 2009; Inaba et al., 2010;
Kunda and Baum, 2009; Toyoshima and Nishida, 2007).
E-cadherin, a component of the adherens junctions, is member of a family
of functionally related transmembrane glycoproteins that mediate calciumdependent cell adhesion and maintenance of epithelial structures. The
ectodomain of E-cadherin mediates homophilic ligation between epithelial cells,
while the cytoplasmic tails of E-cadherin interact with p120-catenin and β-catenin
to link E-cadherin to the actin cytoskeleton (van Roy and Berx, 2008). In the
mammary gland, E-cadherin is expressed in luminal epithelial cells, and has
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been shown to play a role in the maintenance of differentiation, integrity of
luminal cell-cell contacts, assembly of other junctional components including tight
junctions and desmosomes, and correct apicobasal cell polarity within alveolar
structures (Daniel et al., 1995). Blocking the function of E-cadherin with specific
antibodies has been shown to effect cell division and overall integrity of alveolar
structures (Daniel et al., 1995), highlighting the importance of E-cadherin in
breast epithelial morphogenesis. Adherens junctions, and specifically E-cadherin,
are the site of interaction between the cell cortex and the astral microtubules,
which are the guiding microtubules during orientation of the mitotic spindle (Ligon
and Holzbaur, 2007). A study performed by den Elzen et al in 2009 demonstrated
that E-cadherin was required for proper planar cell division within mammalian
epithelial cells (including in MCF10A breast epithelial cells), and in the absence
of E-cadherin, proper mitotic spindle orientation was perturbed (den Elzen et al.,
2009). A requirement for E-cadherin in the establishment of proper mitotic
spindle orientation has also been demonstrated in the drosophila epithelium
(Inaba et al., 2010).
In a tumor setting, disruption of adherens junctions and decreased Ecadherin expression has been associated with and contributes to the epithelialto-mesenchymal transition, increased proliferation and invasion in many types of
cancer including breast cancer and is therefore thought of as a tumor suppressor
protein. The vital role E-cadherin plays in the establishment of epithelial polarity
and proper mammary gland morphology, its role in regulating mitotic spindle
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orientation and its role as a tumor suppressor protein prompted us to inquire into
the regulation of E-cadherin, specifically in the mammary gland.
The interaction of E-cadherin with the cytoskeleton, and thus the ability of
E-cadherin to form cell-cell adhesions, is tightly regulated by tyrosine
phosphorylation (Roura et al., 1999). Until recently, it was thought that regulation
of adherens junctions was carried out by phosphorylation of β-catenin and p120catenin directly by the non-receptor tyrosine kinase Src. Src phosphorylation of βcatenin and p120-catenin was shown to disrupt adherens junctions and cause
dissociation of E-cadherin from the cytoskeleton (Behrens et al., 1993; Reynolds
et al., 1994)

More recently, it has been demonstrated that Src can directly

phosphorylate E-cadherin, which leads to the recruitment and binding of the E3ligase Hakai (Fujita et al., 2002; Shen et al., 2008). Hakai ubiquinates E-cadherin
leading to its degradation (Shen et al., 2008), consistent with the hypothesis that
Src directs E-cadherin away from a recycling endosome pathway into a
lysosomal targeting pathway (Palacios et al., 2005). The ability of Src to mediate
de-regulation of E-cadherin is further shown by the fact that inhibition of Src
restores e-cadherin-mediated adhesion in breast cancer cells and reduces
migration (Nam et al., 2002). Despite what is known, the relationship between
Src and E-cadherin is complicated. Src has been shown to have a biphasic effect
on E-cadherin function. At low levels of activation, Src exerts a supportive role of
E-cadherin function and positively regulates E-cadherin-mediated cell adhesion,
yet at higher levels of activation, Src impacts E-cadherin adhesion negatively
(McLachlan et al., 2007). Src is found to be elevated in many different types of
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cancer (Irby and Yeatman, 2000) and is associated with altered adhesion of the
cell to the extracellular matrix (Jones et al., 2002). In colorectal cancer cells,
overexpression of Src induced EMT, characterized by disorganization of Ecadherin and enhanced assembly of dynamic αvβ1 integrin-mediated focal
adhesion-like structures (Avizienyte et al., 2002; Avizienyte et al., 2004) It was
also observed that Src was localized to newly formed matrix adhesion sites
(Avizienyte et al., 2002) whereas Src is commonly found to co-localize with Ecadherin at the sites of cell-cell adhesion (Calautti et al., 1998; Owens et al.,
2000). Localization of Src at matrix adhesion sites requires Src-dependent
tyrosine phosphorylation of focal adhesion kinase (FAK) (Avizienyte et al., 2002),
suggesting Src-FAK signaling leads to a switch in adhesion type preference from
E-cadherin mediated adhesion to integrin-mediated adhesion, and promotes a
more motile phenotype. In accordance, expression of a Src-inactivating kinase in
colon cancer cells decreases the number of focal adhesions and promotes Ecadherin-mediated cell-cell adhesion (Rengifo-Cam et al., 2004).
FAK is a protein tyrosine kinase recruited to sites of integrin clustering via
interactions between its c-terminal domain and integrin-associated proteins
paxillin and talin (Mitra et al., 2005). FAK association with β-integrins facilitates its
activation by mediating autophosphorylation of FAK at Y397 (Mitra et al., 2005).
Integrin-stimulated FAK phosphorylation at Y397 leads to conformational
changes in FAK and creates a high-affinity binding site for the Src-homology 2
domain of Src-family tyrosine kinases (Playford and Schaller, 2004). The SrcFAK signaling complex further phosphorylates FAK on several tyrosine residues,
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including Y576, Y861 and Y925 (Mitra et al., 2005; Playford and Schaller, 2004).
Activated FAK at sites of αvβ1 integrin clustering has been shown to mediate the
process of fibronectin (FN) matrix assembly, a process important for
embryogenesis, wound healing and blood vessel formation (Francis et al., 2002;
George et al., 1993). Fibronectin matrix assembly occurs when FN, secreted as a
soluble dimer, is converted into an insoluble fibrillar structure in the extracellular
matrix. Binding of soluble FN to αvβ1 integrin at the cell surface leads to the
formation of focal adhesions, allowing for FN dimers to interact with one another
to form insoluble FN fibrils in the ECM

(Wierzbicka-Patynowski and

Schwarzbauer, 2003). Interestingly, it was recently demonstrated by Quinn et al
that the process of fibronectin matrix assembly is required for GPER-dependent
transactivation of the EGFR in MDA-MB-231 breast cancer cells (Quinn et al.,
2009). Quinn et al demonstrated that E2 activation of GPER lead to Gβγ-subunit
protein-dependent activation of αvβ1 integrin, and activation of αvβ1 integrin is a
prerequisite event for EGFR transactivation (Quinn et al., 2009). Quinn and
colleagues were unable to measure FAK autophosphorylation (Y937) after GPER
activation; and they attribute this to the possibility that GPER activation in MDAMB-231 cells doesn’t generate enough αvβ1 integrin activation to permit FAK
activation; however, a role for E2 in fibronectin matrix assembly is demonstrated
by the requirement for GPER (Quinn et al., 2009). E2-induced upregulation of
Src and FAK have been observed in MCF-7 breast cancer cells (Planas-Silva et
al., 2006; Planas-Silva and Waltz, 2007). E2 can induce cytoskeletal remodeling
and EMT in endometrial cancer cells through activation of Src and FAK, and E2-
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dependent migration was blocked with Src inhibitor PP2 in these cells (Acconcia
F, Endocrinology, 2006).
These observations taken together (E-cadherin-induced regulation of
mammary gland morphology and spindle orientation, Src-FAK-mediated deregulation of E-cadherin, E2-induced regulation of Src, FAK and E-cadherin,
GPER-dependent activation of Src, and the requirement of FN matrix assembly
in GPER-dependent transactivation of the EGFR) led us to hypothesize that E2 is
mediating breast epithelial morphogenesis through a mechanism involving SrcFAK-mediated downregulation of E-cadherin and altered regulation of mitotic
spindle orientation.
To further investigate if E2-induced breast morphogenesis is mediated by
GPER, proceeding through alterations in E-cadherin expression and mitotic
spindle orientation we employed two models; human breast tissue culture ex vivo
and MCF10A breast epithelial cells grown in a three-dimensional environment.
As we have demonstrated that E2 and G-1 induce proliferation in human breast
tissue stimulated for one week ex vivo (chapter 2), and evidence from ER -/transgenic mice demonstrate E2’s role in morphologic homeostasis of the
mammary gland, we were interested in the effect of E2 and GPER-selective
agonist on mammary gland morphology in normal human breast tissue cultured
ex vivo as previously described (Eigeliene et al., 2006)).
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3.3 Results
3.3.1 Estrogen and G-1 induce distinct morphological changes in breast tissue
Human breast tissue was cultured ex vivo on a raft culture system, as
previously described in chapter 2. Tissue was stimulated for 7 days in culture
with control (sham), E2, G-1 and combinations of E2/G-1 and GPER-selective
antagonist G36. Tissue was fixed, paraffin embedded and sectioned. Tissue
sections were stained with hematoxylin and eosin (H&E) to detect changes in
morphology as a result of stimulation with E2 or G-1. Histological examination of
human breast tissue revealed that that alveolar and ductal epithelia retained
morphologic structure throughout the culture period of seven days when
compared to tissue fixed at zero time, before the addition of treatments (Fig
3.3a). The human mammary gland consists of a network of ducts converging at
the nipple. A cross section of a mammary duct is shown in figure 3.2. In the
center of the duct is the lumen, into which milk is secreted and stored during
lactation. Surrounding the lumen is a single layer of luminal epithelial cells,
responsible for synthesis of milk products during terminal differentiation. Adjacent
to the luminal epithelial cells is a single layer of contractile myoepithelial cells,
surrounded by the basement membrane.
Treatment of breast tissue with vehicle alone for one week did not induce
changes in morphology, and ductal cross sections maintained proper morphology
similar to the cartoon structure (Fig 3.3a A). Conversely, we observed that
treatment with E2 for one week resulted in an increase in alveolar epithelial wall
thickness (epithelial height; Fig 3.3a B) when compared to control treated
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samples (Fig 3.3a A). Treatment with GPER agonist G-1 had no effect on
epithelial height within alveolar structures; however G-1 did increase the luminal
area within alveolar structures compared to control tissue samples (Fig 3.3a C).
In order to determine if these effects were significant, epithelial height and
luminal area measurements were carried out using Metamorph image analysis
software. Metamorph quantitation revealed that E2 treatment over seven days in
culture does stimulate a significant increase in human breast tissue when
compared to control treated tissues (Fig 3.3b A). Metamorph quantitation also
revealed that G-1 leads to a significant increase in luminal area, an effect that we
observed by histological analysis of H&E stained tissue sections (Fig 3.3b B)
The increase in luminal area seen with G-1 stimulation was not seen in control
treated tissue, tissue treated with E2, GPER-selective antagonist (G36) alone, or
a combination of E2 and G36 (Fig 3.3b B). In breast tissue samples treated with
a combination of G36 and G-1, GPER-selective antagonist G36 was able to
significantly reduce the luminal area increase induced by treatment with G-1 (Fig
3.3b B).
To

this

point,

we

have

observed

E2-induced,

GPER-dependent

proliferation both in MCF10A cells and in human breast tissue (chapter 2) as well
as distinct morphologic changes in breast epithelium as a result of E2 and G-1
stimulation (Fig 3.3a, b). A possible mechanism coupling increased proliferation
in breast tissue to changes in morphology is an alteration in the mitotic spindle
orientation. As described earlier, mitotic spindle orientation determines the plane
of cytokinesis, and thus the positioning of daughter cells at the end of mitosis. An
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example of parallel versus perpendicular mitotic spindle orientation and the
resulting placement of daughter cells is shown in Figure 3.1. It was
demonstrated that E2 induces a rotation in the mitotic spindle in hormone
dependent tissues, including the prostate and endometrium (Gunin, 2001; Liu et
al., 2008). We were interested if activation of estrogen receptors in the breast
epithelium, including GPER, is able to alter spindle orientation during mitosis,
since this could explain the morphologic changes we observe in breast tissue.
Increased proliferation in luminal epithelial cells in which the mitotic spindle is
predominately oriented parallel to the basement membrane could presumably
lead to alveolar or ductal structures in which the lumen is enlarged, similar to
what we observe in the G-1 treated breast tissue (Fig 3.4A). In contrast,
increased proliferation in luminal epithelial cells in which the mitotic spindle has a
perpendicular orientation relative to the basement membrane could possibly lead
to multiple luminal epithelial cell layers, which is what we observe in the E2
treated breast tissue (Fig 3.4B).
To determine the role of GPER activation in mitotic spindle orientation, we
used a well characterized model of breast epithelial morphogenesis; MCF10A
cells grown in a 3-D environment on Matrigel™ basement membrane. MCF10A
cells are non-transformed breast epithelial cells, and when cultured on a
basement membrane exhibit morphologic properties similar to alveolar structures
in the human mammary gland (Debnath et al., 2003). When seeded on a layer of
basement membrane in a chamber slide (Fig 3.5), MCF10A cells follow a strict
order of events including proliferation to form multicellular structures, polarization,
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survival of outer cell layer and apoptosis of cells in the lumen. It was
demonstrated in chapter two of this study that E2 and G-1 induce proliferation in
MCF10A cells in a 3-D environment. Their ability to proliferate in response to E2
and G-1 stimulation, together with their ability to from hollow, polarized structures
similar to the human mammary gland, make MCF10As a good model to study
mitotic spindle orientation.

3.3.2 Estrogen and G-1 treatment of MCF10A cells alters mitotic spindle
orientation in a 3-D environment
MCF10A cells were grown in 8-well chamber slides as previously
described (Debnath et al., 2003). Once cells had formed multicellular structures
at day four, E2 and G-1 were added to the culture media. MCF10A spheroid
structures were stimulated with E2 and G-1 for six days in culture, fixed and
immunolabeled with phospho-histone H3 (green) to distinguish proliferating cells,
and co stained with anti-α-tubulin (red), which labels microtubules, components
of the spindle apparatus. Images of MCF10A acini containing mitotic cells were
captured with confocal microscopy, and mitotic cells were categorized as either
―parallel‖ or ―perpendicular‖ based on their mitotic spindle orientation relative to
the basement membrane. Cells in which the mitotic spindle was positioned from
0˚ to 45˚ to the basement membrane of the epithelium were regarded as parallel
oriented (Fig 3.6A, B). Mitotic cells with poles aligned from 45˚ to 90˚ to the
plane of the basement membrane were considered to be perpendicular oriented
(Fig 3.6C, D). The ratio of mitotic MCF10A cells with either parallel or
perpendicular mitotic spindles was quantified per treatment group (Fig 3.6E). E2
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treatment caused a significant increase of mitotic cells with a perpendicular
oriented mitotic spindle apparatus when compared to control treated cells (Fig
3.6E). Treatment of MCF10A cells with G-1 did not induce a change the
orientation of the mitotic spindle when compared to control treated cells, although
there was a slight increase in the number of parallel oriented mitotic cells in the
G-1 treated sample (Fig 3.6E), thus G-1 stimulation seem to preferentially
promote a parallel mitotic spindle orientation in MCF10A cells.

3.3.3 Activation of GPER in human breast tissue decreases E-cadherin protein
expression at epithelial junctions in human breast tissue
The molecular regulation of mitotic spindle orientation in polarized
epithelial cells remains under investigation, although there is evidence that
spindle orientation is guided by cellular adhesion proteins, specifically E-cadherin
(den Elzen et al., 2009; Le Borgne et al., 2002). E-cadherin is expressed
between luminal epithelial cells in the mammary gland at adherens junctions (Fig
3.7). E-cadherin is a calcium dependent cell adhesion molecule that is linked to
the actin cytoskeleton through its interaction

-catenin. Antibody-mediated

disruption of E-cadherin-mediated adhesion in the mammary gland causes
dissociation of the epithelium (Daniel et al., 1995), indicating the importance of
this cell adhesion molecule in the maintenance of breast epithelial integrity.
Further support for E-cadherin’s role in mammary gland morphogenesis comes
from a transgenic mouse model in which a dominant negative (DN) E-cadherin
was expressed in the mammary gland (Delmas et al., 1999). During lactation in
these mice, DN E-cadherin caused a decrease in cell-cell adhesion, discontinuity
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of the basement membrane and a loss of epithelial polarity. E-cadherin’s ability to
regulate morphogenesis and polarity in a hormone responsive tissue indicates
that it might also play a role in regulating mitotic spindle orientation.
To investigate the relationship between GPER activation and E-cadherin
expression in the mammary gland, human breast tissue was treated for seven
days with control, E2 or G-1, fixed, paraffin embedded and sectioned. Sections of
breast tissue were immunolabeled with an antibody against E-cadherin. Confocal
microscopy was used to capture images of E-cadherin staining in mammary
tissue, and E-cadherin fluorescence intensity relative to total area of alveolar
structures was determined with Slidebook image analysis software.
As expected, E-cadherin was found to be expressed and localized in
breast tissue alveolar and ductal structures at cellular junctions in untreated
tissue (Fig 3.8A). E-cadherin protein expression, measured by fluorescence
intensity, was increased in a dose dependent manner in breast tissue treated
with E2 (Fig 3.8C-E, I) when compared to sham treated tissue (Fig 3.8B).
Although the E2-induced increase in junctional E-cadherin staining was not found
to be significant (p = .0588), the trend is apparent from the images and the
quantitation (Fig 3.8C-E, I). Treatment of breast tissue with G-1 had an opposite
effect on E-cadherin protein expression. G-1 stimulation led to a dose dependent
decrease in E-cadherin protein expression (Fig 3.8F-H), with 100nM G-1
stimulation leading to a significant decrease in E-cadherin protein expression
when compared to control treated breast tissue (Fig 3.8I).
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It is possible that G-1-induced E-cadherin protein downregulation is
mediated by Src-FAK induced phosphorylation of E-cadherin or its binding
partners, leading to its internalization and degradation, since this mechanism has
previously been reported (Shen et al., 2008). Although there is little evidence
directly linking FAK phosphorylation to E-cadherin de-regulation, a study from
2002 revealed that phosphorylation of FAK on Src-specific sites is required for
Src-induced downregulation of E-cadherin in colon cancer cells (Avizienyte et al.,
2002). It has also been shown that there is a role for Src-FAK-dependent
signaling in the transition from E-cadherin mediated cell adhesion to integrinmediated signaling, thus the promotion of a more motile phenotype of cancer
cells (Avizienyte et al., 2002; Rengifo-Cam et al., 2004). This data, coupled with
an observed E2-induced FAK upregulation in MCF-7 breast cancer cells (PlanasSilva and Waltz, 2007), and the requirement of fibronectin matrix assembly (of
which FAK phosphorylation is an important step (Wierzbicka-Patynowski and
Schwarzbauer, 2003)) in GPER-dependent transactivation of the EGFR (Quinn
et al., 2009) prompted us to investigate whether GPER activation in MCF10A
cells leads to increased FAK phosphorylation.

3.3.4 Activation of GPER increases FAK phosphorylation in MCF10A cells
MCF10A cells were stimulated for 5 or 10 minutes with vehicle, E2, or G1, lysed and protein extracted for western blot analysis. Western blots containing
MCF10A

cell

lysates

were

probed

for

FAK

activation;

(Y397),

the

autophosphorylation site that becomes activated on FAK recruitment to focal
adhesions (Mitra et al., 2005). Western blot analysis revealed that 100nM G-1 led
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to a significant increase in phosphorylated FAK after ten-minute stimulation (Fig
3.9). E2 also led to an increase in FAK activation at 10 minutes, although the
increase was not significant (Fig 3.9). Stimulation with positive control EGF also
induced FAK phosphorylation after five minutes of stimulation when compared to
control treated cells at the equivalent time point (Fig 3.9).
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3.4 Discussion
E2 plays an important role in promoting proliferation and branching
morphogenesis during development (Brisken and O'Malley, 2010). E2’s ability to
promote proliferation and influence morphogenesis in the breast apart from a
developmental setting has also been demonstrated (Eigeliene et al., 2006). The
overall goal of this study was to determine if GPER mediates E2-induced
processes in the breast including proliferation and epithelial morphogenesis.
Since we demonstrated in chapter 2 that E2-induced proliferation in breast tissue
was partially dependent on GPER, we investigated here whether GPER
activation promotes morphologic changes in mammary epithelium, and possible
mechanisms regulating GPER-dependent morphogenesis.
We used a previously characterized ex vivo model ((Eigeliene et al., 2006)
to culture human breast tissue for seven days in the presence of control, E2, or
GPER-selective agonist, G-1, and antagonist, G-36 We found that after one
week of stimulation with E2, alveolar structures had an increased epithelial height
(Fig 3.3a B) when compared to control treated tissue (Fig 3.3a A); an effect
previously demonstrated (Eigeliene et al., 2006). G-1 stimulation had no effect on
the epithelial height, nor was G36 able to abrogate the E2-induced increase in
epithelial height, suggesting this effect is mediated by classical ER’s and not
GPER. G-1 stimulation did however lead to an increase in the luminal area (Fig
3.3a C) when compared to control treated tissue, and this effect was abrogated
by GPER-selective antagonist G36, suggesting this effect is mediated by GPER
in breast tissue. Human breast tissue does express both classical ER’s and
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GPER (Fig 2.10 C, D), so it is possible that E2 is mediating different
morphological effects through both receptors. It is interesting that E2 didn’t
stimulate an increase in luminal area in addition to an increase in epithelial
height, since E2 is able to activate both ERα/β and GPER. This data suggests
that E2-induced epithelial height increase (mediated by ERα) is a dominant
phenotype relative to increased luminal area mediated by GPER. A future
experiment to determine if this hypothesis is correct would be to culture breast
tissue with both E2 and G-1, and see the resultant phenotype (increased
epithelial height vs. increased luminal area). This experiment could also be
modified to include tamoxifen in combination with E2 and G36. Tamoxifen in the
breast acts as an anti-ERα yet is also able to activate GPER. I would hypothesize
breast tissue treated with E2, tamoxifen and G36 would retain a morphology
similar to control treated tissue, since tamoxifen would inhibit E2-induced
activation of ERα (presumably inhibiting increased epithelial height) and G36
would inhibit tamoxifen-induced activation of GPER (presumably inhibiting
increased luminal area).
We have demonstrated E2- and G-1-dependent proliferation in human
breast tissue as well as MCF10A breast epithelial cells (Figure 2.1, 2.3, 2.10).
We have also observed distinct changes in morphology resultant from E2-and G1-stimulation of breast tissue. Since mitotic spindle orientation is directly linked to
proliferation and to the morphogenesis and organization of epithelial structures,
and because it has been observed that E2 promotes a rotation in the mitotic
spindle apparatus during proliferation of the hormone-responsive murine uterus,
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we chose to investigate whether E2-induced regulation of mitotic spindle
orientation is mediated by GPER. Immunofluorescence analysis of MCF10A cells
grown in 3-D cultures, labeled with mitosis marker p-histone H3 and an antialpha tubulin antibody revealed that E2 promotes a rotation of the mitotic spindle
to that of a perpendicular orientation relative to the basement membrane (Fig
3.6C-D, E) in a significant number of cells, whereas control treated cells
maintained a predominately parallel mitotic spindle orientation relative to the
basement membrane (Fig 3.6A-B, E). While G-1 didn’t stimulate a rotation in the
mitotic spindle apparatus, acinar structures with increased G-1-induced
proliferation, coupled with a predominately parallel oriented mitotic spindle could
presumably result in an increased luminal area, similar to what we observe in G1 treated breast tissue. Although the spindle orientation results observed in
MCF10A cells agree with the morphologic phenotypes we see with E2 and G-1stimulation of breast tissue, MCF10A cells only express one ER, GPER, unlike
human breast tissue, which expresses all three, ERα/β and GPER. Qualitatively
distinct GPCR activation through different ligands has previously been described
(Mailman, 2007; Violin et al., 2010; Zidar et al., 2009) and it is possible that G-1
and E2 are promoting differential effects on mitotic spindle orientation mediated
through the same receptor, GPER, in MCF10A cells.
We next asked if we could identify a cellular event linking E2 and G-1
stimulation to the spindle apparatus. Because there is evidence that E-cadherin
can regulate mitotic spindle orientation in epithelial cells, and evidence of E2induced de-regulation of E-cadherin at cell-cell junctions (Oesterreich et al.,
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2003), we inspected E-cadherin expression in human breast tissue by confocal
microscopy. E2 and G-1 had dissimilar effects on E-cadherin expression in
human breast tissue; not surprising given that this tissue expresses all three
estrogen receptors (ERα/β and GPER), and because the tissue responded
differently to E2 and G-1 in terms of morphological characteristics. Breast tissue
treated with E2 showed increased E-cadherin expression in a dose-dependent
manner (Fig 3.8C-E), although the difference was not statistically significant
relative to control treated tissue (Fig 3.8B). Treatment of tissue with G-1 reduced
E-cadherin expression in a dose-dependent manner at cell-cell junctions (Fig
3.8F-H) when compared to control treated tissue. Our results showing E2induced E-cadherin downregulation don’t agree with previous a previous report of
E2-induced upregulation of E-cadherin (Oesterreich et al., 2003); however this
study was carried out in breast cancer cells, indicating E-cadherin regulation may
be complicated by tissue type and normal vs. tumorigenic state. The G-1-induced
downregulation we observe in human breast tissue is interesting in light of the G1-increased luminal size we also observe in human breast tissue. In mice,
disruption of E-cadherin in the mammary gland led to dissociation of the epithelial
layer (Daniel et al., 1995). An interesting hypothesis to consider is that similar to
blocking E-cadherin function with an antibody, G-1-mediated downregulation of
E-cadherin at cell-cell junctions could be causing a slight dissociation, or
loosening of the luminal epithelial layer, which when coupled to an increase in
proliferation could lead to alveolar structures with enlarged lumens. A way to test
this hypothesis would be to determine if GPER-selective antagonist G36 can
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restore E-cadherin expression. It would also be interesting to see the effect on Ecadherin protein expression in breast tissue treated with both E2 and G-1, in
order to determine which ligand (and/or receptor) has preference in terms of Ecadherin regulation. These experiments could also be carried out in MCF10A
cells, where we would expect E2 and G-1 to induce E-cadherin downregulation
since MCF10A cells only express GPER; however the differential effects due to
E2 and G-1 on mitotic spindle orientation complicate this hypothesis.
A

common

mechanism

to

regulate

E-cadherin

expression

is

phosphorylation of E-cadherin cytoplasmic domain directly, or its binding partner
β-catenin, by the non-receptor tyrosine kinase Src (Owens et al., 2000).
Phosphorylation of E-cadherin has been shown to lead to its internalization and
ubiquitin-mediated degradation (Fujita et al., 2002; Shen et al., 2008). A well
known binding partner of Src, FAK, is also thought to mediate the
phosphorylation and downregulation of E-cadherin (Quadri, 2012). In the context
of GPER signaling, Src is known to be activated downstream of GPER, and
fibronectin matrix assembly (a process that recruits FAK to focal adhesions at the
membrane) is required for GPER-dependent EGFR transactivation (Quinn et al.,
2009). We demonstrated in chapter two that Src is required for GPER-dependent
proliferation in MCF10A cells (Fig 2.5C), so we next determined if E2 or G-1
stimulation modulated FAK activation in MCF10A cells. By western blot analysis
we demonstrated that E2 and G-1 stimulate an increase in p-FAK (Y397), and
the G-1-induced increase in p-FAK is significant at 10 minute stimulation (Fig
3.9)
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Observations to this point suggest that activation of GPER in the
mammary gland leads to an increase in Src and FAK. These kinases could
presumably phosphorylate E-cadherin at cell-cell junctions, leading to the deregulation of E-cadherin and downstream morphological consequences of this
could include breast epithelial structures with increased lumen size. Data also
suggests that classical ERs are also contributing to breast epithelial
morphogenesis by promoting changes in mitotic spindle orientation during
cellular proliferation. More work will be needed to elucidate the specific
mechanism of E2-induced breast epithelial morphogenesis; however it is
apparent that GPER is contributing to this process.
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3.5 Materials and Methods
3.5.1 Reagents
Dulbecco’s Modified Eagle Medium (DMEM), phenol red-free DMEM, E2,
fetal bovine serum (FBS), normal goat serum (NGS), insulin, cholera toxin,
transferrin, hydrocortisone and prolactin were from Sigma (St. Louis, MO).
Recombinant epidermal growth factor (EGF) and penicillin/streptomycin (P/S)
were from Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA) was from
Amresco (Solon, OH). Growth factor reduced phenol red-free Matrigel™ was
from BD Biosciences (San Jose, CA). G-1 was synthesized as described (Bologa
et al., 2006) and provided by Jeffrey Arterburn (New Mexico State University, Las
Cruces, NM). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA). Small
interfering RNA (siRNA) was purchased from Dharmacon RNAi Technologies
(Dharmacon, Lafayette, CO): ON-TARGET plus SMARTpool siRNA for GPER (L005563-00) and ON-TARGETplus siControl Non-Targeting siRNA (D-00181002).

3.5.2 Inhibitors and antibodies
G36 was synthesized as described (Dennis et al., 2011) and provided by
Jeffrey Arterburn (New Mexico State University). Rabbit p-Histone H3 antibody
and mouse β-actin antibody were from Millipore (Billerica, MA). Mouse anti-Ecadherin antibody and mouse antiphospho-FAK (Y397) antibody were from BD
Biosciences (San Jose, CA). Mouse anti-α-tubulin antibody was from Sigma (St.
Louis, MO). Goat antirabbit IgG-Alexa 488-conjugated secondary antibody and
Goat antimouse IgG-Alexa 533-conjugated secondary antibody were from
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Invitrogen (Carlsbad, CA). Goat antirabbit IgG-HRP-conjugated antibody was
from GE Healthcare (Princeton, NJ) and goat antimouse IgG-HRP-conjugated
antibody was from Cell Signaling.

3.5.3 Cell Culture
Immortalized, non transformed MCF10A human breast epithelial cells
(ATCC, Manassas, VA; catalog number CRL-10317) were maintained in
MCF10A complete media (DMEM/F-12 supplemented with 5% dextran-charcoalstripped fetal bovine serum, 10 μg/mL insulin, 100 ng/mL cholera toxin, 0.5
μg/mL hydrocortisone, 20 ng/mL recombinant epidermal growth factor and 1%
penicillin/streptomycin). Cells were cultured in a humidified atmosphere
containing 5% CO2 at 37◦C. Overnight cell synchronization for immunoblot
analysis was performed as previously described (Chou et al., 1999). After
overnight synchronization, cells were stimulated for 24 hours with vehicle control,
17-beta estradiol (1nM to 100nM) (E2), G-1 (GPER-selective agonist) (1nM to
100nM), and G36 (GPER-selective antagonist; 5nM to 500nM).
MCF10A cells were also grown in Growth Factor Reduced phenol red-free
Matrigel™ on 8-well chamber slides (BD Falcon, San Jose, CA). Approximately
5,000 MCF10A cells were seeded on 40µL of Matrigel in each chamber on the
slide. Cells were suspended in growth media (described above) supplemented
with 2% Matrigel. The media was changed every two days, and after four days in
culture, various treatment compounds (described above) were added to growth
media. Cells continued to grow in Matrigel until day 10, whereby they were fixed
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with 4% PFA in PBS for 15 minutes at room temperature. Immunofluoresence
assays were carried out of MCF10A cells in 2D and 3D according to a method
previously described (Debnath et al., 2003). Images were captured on a Zeiss
LSM 510 confocal microscope (Carl Zeiss Inc., Oberkochen, Germany), using
x400 total magnification and an optical thickness of 0.7 µM.

3.5.4 Tissue Samples
Human breast tissue was acquired from female patients who were
undergoing reduction mammoplasty surgery between November 2007 and
January 2011. Normal breast tissue remaining after pathological testing was
collected and used in this study. Successive specimens were collected at
University of New Mexico hospital (UNMH), and received from the cooperative
human tissue network (CHTN Western division- Vanderbilt University, Nashville,
TN), a division of the National Cancer Institute. This study protocol was approved
by University of New Mexico Health Sciences Center institutional review board
(IRB). Tissue collected at UNMH was transported to the laboratory on ice in DMEM/F-12 medium containing 1% P/S, within 1-2 hours of surgery. Tissue
obtained from CHTN was shipped overnight on ice in RPMI medium (Sigma)
supplemented with 1% P/S. The tissue was dissected into 3 mm3 pieces in
phenol-red free D-MEM/F-12 medium in order to exclude as much adipose
tissues as possible, saving the collagenous connective tissue where the epithelial
ducts and lobules are found
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3.5.5 Organ Culture
Breast tissue was incubated according to a previously described method
(Eigeliene et al., 2006), in which pieces of breast tissue are placed on sterile lens
paper lying on stainless steel grids (our protocol modified this to use nylon grids)
atop a 35mm tissue culture dishes inside a 10cm dish. For experiments done in
breast tumor tissue, tissue was submerged in media in a 24 well plate. Tissue
was incubated overnight in a humidified atmosphere with a mixture of 5% CO2
and 95% air at 37˚C in phenol-red free D-MEM/F-12 medium supplemented with
1% P/S, 10ug/mL insulin, 3ug/mL prolactin, 4mg/ml transferrin and 1ug/mL
hydrocortisone. Following overnight incubation to ―rest‖ the tissue, additions were
made to the medium in the inner tissue culture dish; including vehicle control, 17beta estradiol (1nM to 100nM) (E2), G-1 (GPER-selective agonist) (1nM to
100nM), and G36 (GPER-selective antagonist; 5nM to 500nM). Compounds
were diluted in dimethylsulfoxide (DMSO); therefore control tissues were
incubated in media supplemented with DMSO vehicle. Growth media was
changed every two days and fresh treatments were added. Tissue was collected
7 days after the addition of treatments and fixed in 4% paraformaldehyde (PFA)
in phosphate buffered saline (PBS) overnight at room temperature.

3.5.6 Tissue histology and Image Analysis
Tissue was dehydrated, embedded in paraffin, and sectioned. Paraffin
sections (5µm) were mounted on Super-Frost Plus slides (Menzel- Gläser,
Germany). After rehydrating sections through graded alcohol series followed by
water, tissue was stained with hematoxylin and eosin (H&E) for histological
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examination. Images were obtained under light microscopy at x400 magnification
with the aid of a Zeiss 200M Axiovert inverted microscope (Carl Zeiss Inc.,
Oberkochen, Germany) and morphological measurements were made using
metamorph

image

analysis

software

(Molecular

devices,

Union

CA).

Histomorphometric evaluation was carried out to determine the effects of
different treatment on epithelial morphology. All morphometric measurements
were done on H&E-stained sections. Using a digital drawing system run by
Metamorph, acinar structures were measured by outlining luminal epithelial cell
layers, and the luminal space on the monitor screen with the computer mouse.
Epithelial height (µm) was calculated as an average of 8 cross-sectional lines
traced from the within the luminal epithelial cell layer, and luminal area (µm2) was
calculated by tracing the empty space within the luminal epithelial cells.

3.5.7 Indirect Immunofluorescence (Tissue)
For immunofluorescence staining, paraffin sections (5µm) were mounted
on Super-Frost Plus slides (Menzel- Gläser, Germany). After rehydrating
sections through a graded alcohol series followed by water, the slides were
treated for antigen retrieval by boiling in a microwave oven in 0.01 M citrate
buffer (pH 6.0) for 20 minutes. After a series of washes the sections were
incubated with 0.1% Triton X-100 containing 3% NGS for 30 min at room
temperature to permeabilize cells and block non-specific binding antibody. Tissue
sections were then incubated with primary antibodies diluted in PBS + 0.1%
Tween-20 containing 3% NGS overnight at 4°C in a humid chamber. Following
overnight incubation with primary antibody, tissue sections were washed and
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incubated with species-matched Alexafluor conjugated secondary antibodies
(Invitrogen) for 1 hour at room temperature in a dark chamber. Sections were
incubated for 15 minutes with Topro-3 (Molecular Probes) to stain nuclei.
Sections were mounted with Vectashield mounting media (Vector Labs) and
sealed with nail polish. Images were captured on a Zeiss 200M Axiovert inverted
microscope (Carl Zeiss Inc., Oberkochen, Germany) using x400 total
magnification.

3.5.8 Western Immunoblotting
Cells were lysed in RIPA buffer supplemented with buffer supplemented
with

sodium

fluoride

(50

mM),

sodium

orthovanadate

(1

mM),

phenylmethylsulfonylfluoride (1 mM), and protease cocktail (1X). Cell lysate
protein concentration was determined by performing a Bradford protein assay
(Bio-rad, Hercules, CA). Equal protein concentrations per lysate were loaded on
a 4-20% SDS-PAGE gel (Thermo-Scientific, Rockford, IL) and then transferred to
polyvinylidene difluoride membranes (Millipore, Billerica, MA). After blocking in
5% nonfat dry milk for 1 hour at room temp, the membranes were incubated with
primary antibodies at a 1:100 to 1:10,000 dilution in 3% BSA overnight at 4˚C
with gentle rocking. After a series of washing, the blots were then incubated with
horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG
at 1:10,000 in 3% BSA for 1 hour at room temperature with gentle rocking. The
blots were developed using Supersignal West Pico Chemilumiscent Substrate
(Thermo Fisher). Films were then scanned and quantified using ImageJ software
(National Institutes of Health, Bethesda, MD).
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3.5.9 Cell Imaging and image analysis
For E-cadherin image analysis, Slidebook version 4.2 (Intelligent Imaging
Innovations, Denver, CO) was used to determine fluorescence intensity in human
breast tissue. This software measures the intensity of each pixel above a set
intensity threshold in a demarcated area. The number of pixels above a certain
threshold within this area is expressed as a percentage of the total number of
pixels in the selected area.

3.5.10 Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.03 (La
Jolla, CA). Analysis done with a one way analysis of variance (ANOVA) within
Prism estimates the correlation of variables (acinar thickness, luminal area, etc)
with treatment groups (sham, E2, G-1, G-36, etc). Pairwise comparisons of
results between different treatment groups were determined using a one-way
Analysis of Variance (ANOVA) followed by a Dunnett’s test. Data represents the
mean ± SEM of three or more separate experiments. P-values less than 0.05
were considered to be significant.
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3.6 Figure Legends
Figure 3.1 Mitotic spindle orientation in adherent epithelial cells.
A: an example of an epithelial cell undergoing mitosis in which the mitotic spindle
aligns parallel to the basement membrane. This will result in daughter cells that
are next to one another and adjacent to the basement membrane. B: an example
of an epithelial cell undergoing mitosis perpendicular to the basement
membrane. This will result in stacked daughter cells, with one adjacent to the
basement membrane, and the second protruding into the lumen.
Figure 3.2 Illustration of a human mammary gland duct in cross section.
A central lumen is surrounded by a single layer of luminal epithelial cells.
Adjacent to these cells are a single layer of contractile myoepithelial cells,
surrounded by the basement membrane.
Figure 3.3a E2 and G-1 treatment of human breast tissue results in
increased epithelial height and luminal area respectively.
Hematoxylin and eosin staining of human breast tissue cultured ex vivo for one
week with sham (A), 10nM E2 (B) or 100nM G-1 (C) highlights alveolar
morphology. (Scale bar represents 50µM)
Figure 3.3b E2 and G-1 treatment of human breast tissue results in
increased epithelial height and luminal area respectively.
Alveolar epithelial wall thickness (height, A) and luminal area (B) were measured
on epithelial structures in breast tissue cultured ex vivo for seven days in the
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presence of E2, G-1, G36, E2 + G36 or G-1 + G36, and compared with control
treated tissue. Each group consisted of tissue samples from a minimum of five
different patients. Results are expressed as mean ± SEM, and statistical
significance (P ≤ 0.05) was assessed by one-way ANOVA followed by a
Dunnett’s test-test. (*, significantly different relative to sham; #, significantly
different relative to G-1)
Figure 3.4 Hypothetical effect of mitotic spindle orientation on alveolar
morphology in breast tissue.
Breast epithelial proliferation under conditions that increase the percentage of
mitotic spindles with alignment parallel to the basement membrane could result in
alveoli with increased lumen size (A). Proliferation in cells under conditions that
increase mitotic spindle rotation to a perpendicular orientation relative to the
basement membrane could result in alveoli with increased luminal epithelial
layers (B).
Figure 3.5 MCF10A model of breast morphogenesis.
Timeline of events in development of an MCF10A acinar structure grown in a 3-D
environment on Matrigel™ basement membrane. (Figure taken from Debnath et
al, 2003, Methods, 30; p 261)
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Figure 3.6 Estrogen leads to a rotation of the mitotic spindle in MCF10A
cells grown in Matrigel™
Mitotic cells were assessed by immunostaining with anti-pH3 (green) and spindle
orientation was determined by immunostaining with anti-α Tubulin antibody (red).
Mitotic spindles were determined to be either oriented parallel to the basement
membrane (A,B) or perpendicular to the basement membrane (C,D) in cells
grown in the presence of sham, E2 or G-1. Results are expressed as a ratio of
parallel to perpendicular spindle orientation per treatment group and are
presented as mean ± SEM. Statistical significance (P ≤ 0.05) was assessed by
Student’s t-test. (*, significantly different relative to sham perpendicular
percentage).
Figure 3.7 E-cadherin in mammary alveolar structures.
E-cadherin, a calcium dependent transmembrane cell adhesion protein, is
expressed in breast luminal epithelial adherens junctions. E-cadherin interacts in
homotypic fashion with other E-cadherin molecules on adjacent cells. The
intracellular domain of E-cadherin is interacts with the actin cytoskeleton through
β-catenin and α-catenin.
Figure 3.8. G-1 downregulates E-cadherin expression in human breast
tissue.
E-cadherin expression was assessed in untreated human breast tissue (A) or
tissue treated for seven days with Sham (B), E2 (C-E) or G-1 (F-H) by
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immunofluorescence using an anti-E-cadherin antibody (green). Confocal images
were acquired and quantitation of E-cadherin fluorescence intensity was
performed using Slidebook™ image analysis software. The graph represents the
average fluorescence intensity per area (in pixels) of alveolar structures for each
treatment group (I). Each group consisted of tissue samples from a minimum of
five different patients. Results are expressed as mean ± SEM, and statistical
significance (P ≤ 0.05) was assessed by one-way ANOVA followed by a
Dunnett’s test-test. (*, significantly different relative to sham)
Figure 3.9 G-1 induces FAK activation in MCF10A cells.
MCF10A cells were stimulated with indicated concentrations of EGF, E2 or G-1
for 5 or 10 minutes. Lysates were immunoblotted with antibodies specific for
phospho-FAK (representative blot shown here). Equal protein loading was
confirmed with β-actin. Histogram represents fold change in p-FAK protein. Data
are representative of three independent experiments. Results are expressed as
mean ± SEM and statistical significance (P≤ .05) was assessed by one-way
ANOVA followed by a Dunnett’s test. (*, significantly different relative to sham)
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3.7 Figures
Figure 3.1 Mitotic spindle orientation in adherent epithelial cells
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Figure 3.2 Illustration of a human mammary gland duct in cross section
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Figure 3.3a E2 and G-1 treatment of human breast tissue results in increased epithelial
height and luminal area
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Figure 3.3b E2 and G-1 treatment of human breast tissue results in increased epithelial
height and luminal area
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Figure 3.4 Hypothetical effect of mitotic spindle orientation on alveolar morphology in
breast tissue
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Figure 3.5 MCF10A model of breast morphogenesis
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Figure 3.6 Estrogen leads to a rotation of the mitotic spindle in MCF10A cells grown in
Matrigel™
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Figure 3.7 E-cadherin in mammary alveolar structures.
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Figure 3.8 G-1 downregulates E-cadherin expression in human breast tissue
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Figure 3.8 G-1 downregulates E-cadherin expression in human breast tissue
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Figure 3.9 G-1 induces FAK activation in MCF10A cells
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4. GPER REGULATION OF MALE REPRODUCTIVE PHYSIOLOGY
4.1 Abstract
Estrogen (17β-estradiol, E2) is a complex signaling molecule, regulating
physiologic responses in diverse tissues in both male and female reproductive
systems. Classically thought of as the female sex hormone, E2 also has a vital
role in the male reproductive system, specifically in spermatogenesis.
Spermatogenesis (the generation of haploid male gametes from diploid stem
cells) occurs in the seminiferous tubules of the testes. Classical ERs (ERα/β) are
abundantly expressed in cells of the testes and epididymis, the E2 responsive
coiled tube connecting the seminiferous tubules with the vas deferens where
mature sperm undergo maturation. Dependence on E2 for proper testicular
function and spermatogenesis is demonstrated in studies in mice lacking either
ERα or aromatase, the enzyme that converts testosterone into E2. While E2 is
necessary for spermatogenesis and testicular function to occur, exposure to high
dose E2 during development or exposure to environmental estrogens throughout
a

man’s

lifetime

results

in

abnormal

spermatogenesis

and

testicular

development, and decreased sperm counts respectively. E2 is able to negatively
regulate spermatogenesis by inhibiting gonadrotrophin release from the pituitary,
thus interfering with testosterone synthesis.
The novel G protein-coupled Estrogen GPER is expressed in testicular
cells, and contributes to E2 induced rapid cell signaling in the testes. For the
current study we asked if GPER contributed to E2-dependent regulation of
spermatogenesis and epididymal morphology in C57BL/6 mice, which have been
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shown to be extremely sensitive to E2 exposure. At 23 days of age, C57BL/6
mice were subcutaneously implanted with 21-day release pellets containing
placebo (sham), E2 or G-1. At day 44 mice were euthanized and male
reproductive organs were removed for morphological analysis.
We found that while E2 treatment of mice resulted in decreased testes
size, wet weight and spermatogenesis (G-1 had no effect on these
characteristics), G-1 treatment led to an increase in the size of epididymal
lumens. Although the mechanism of this GPER-mediated phenotype was not
established, this finding is intriguing, given that we have also observed strikingly
similar G-1-induced morphological changes in the mammary gland.
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4.2 Introduction
Although long considered to be primarily a female sex hormone, E2 also
exerts a variety of effects on the male reproductive system. E2 plays an
important role in spermatogenesis and thus fertility, which begins with meiosis
and generation of haploid spermatozoa from diploid stem (germ) cells in the
seminiferous tubules of the testes, continuing in the epididymis, the highly coiled
testicular tube connecting the seminiferous tubules to the vas deferens (Joseph
et al., 2011). The testes are located inside a tough membranous coat, the tunica
albuginea, and the tightly coiled seminiferous tubules are enclosed within the
testes. A cross-sectional view of a mouse seminiferous tubule is shown in figure
4.1 The seminiferous tubules are the site of stem cell (spermatogonia) mitosis,
subsequent meiosis (primary and secondary spermatocytes), and finally
spermatogenesis, the generation of morphologically distinct spermatozoa
(Carreau et al., 2012; McLachlan, 2000). The seminiferous epithelium consists of
Sertoli cells, often called ―nurse cells‖, which are tall columnar cells that extend
from the basement membrane into the lumen of the tubule (Fig 4.1). Tucked in
between the Sertoli cells are the spermatogenic cells. Newly differentiated sperm
are transported from the testes by way of the efferent ductuals to the epididymis
(Fig 4.2). The epididymis is a narrow, tightly coiled epithelial tube located
adjacent to the testes. As sperm proceed through the coiled tube of the
epididymis, they undergo further motility-enabling maturation before they enter
the vas deferens (Carreau et al., 2012).
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The testes have a dual role of producing spermatozoa, to promote fertility,
and secreting androgens, including testosterone, to promote generation of male
secondary sexual characteristics (Carreau et al., 2012). Androgens are produced
in the Leydig cells, located in the stroma between seminiferous tubules. These
functions are regulated by the hypothalamus-pituitary-gonadal axis, similar to the
regulation of E2 production in female reproductive physiology (McLachlan, 2000).
Hypothalamic gonadotrophin-releasing hormone (GnRH) drives this process by
inducing pituitary gonadotrophin secretion of both follicle stimulating hormone
(FSH) and luteinizing hormone (LH). FSH acts through its receptors on Sertoli
cells in the testes seminiferous epithelium, where it stimulates primary
spermatocytes to undergo the first division of meiosis, thus producing secondary
spermatocytes (Bliss et al., 2010; Finkelstein et al., 1991). LH acts on Leydig
cells (interstitial cells of Leydig) in the testes to promote testosterone secretion.
LH regulates testosterone production by regulating the expression of 17-β
hydroxysteroid

dehydrogenase,

the

enzyme

responsible

for

converting

androstenedione into testosterone in the Leydig cell (Payne et al., 1987).
Testosterone activates genes in Sertoli cells, promoting differentiation of
spermatagonia

into

spermatocytes,

and

thus

is

required

for

normal

spermatogenesis to occur. Sertoli cells are also induced to produce androgen
binding protein, which binds testosterone as it is synthesized and helps to
concentrate it in the right place to direct spermatogenesis (McLachlan, 2000).
Similar to the regulation of E2 production in the ovaries, endocrine
regulation of testosterone and spermatogenesis involves a negative feedback of
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testosterone on LH and FSH secretion from the pituitary, by inhibiting GnRH
release from the hypothalamus (Bliss et al., 2010; Finkelstein et al., 1991). The
negative feedback of testosterone production is also mediated by inhibin. This
protein, stimulated by androgen secretion, is secreted by Sertoli cells, and acts to
inhibit FSH secretion, thus creating a negative feedback look to regulate
testosterone production (Bliss et al., 2010).
It is known that estrogens, including 17β-estradiol (E2), are involved in the
regulation of growth, differentiation and spermatogenesis of normal human
testes, mediated by classical ERs, ERα/β (Carreau et al., 2012; O'Donnell et al.,
2001). In addition to a supportive and necessary role in testicular function, high
dose E2 exposure in mice during development has been shown to have a
negative impact on spermatogenesis (O'Donnell et al., 2001). Further support for
E2’s negative impact on spermatogenesis is shown in humans, where exposure
to environmental E2s is correlated with decreased sperm count (Sharpe and
Skakkebaek, 1993; Toppari et al., 1996). E2 regulation of testicular function
extends to a tumorigenic setting, where it has been shown that classical ERs
mediate E2ic responses in testicular germ cell tumors (Pais et al., 2003; Rago et
al., 2011).
Expression patterns of classical estrogen receptors ERα/β vary depending
on species. As our experiments were carried out in mice, the following
description of expression and localization of classical ERs is based on the
pattern in rodents. Based on immunohistochemical analysis of the testes, ERα is
observed mainly in Leydig cells, whereas ERβ has been visualized in most of the
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somatic cells of the testes (Hess et al., 1997). Novel estrogen receptor GPER is
also expressed in the testes in both humans (Rago et al., 2011) and rat Sertoli
cells (Lucas et al., 2010). In addition to GPER expression in testicular cells,
GPER is overexpressed in testicular germ cell tumors (Franco et al., 2011).
There is accumulating evidence that GPER mediates rapid, E2-induced
signaling in testicular cells (Chimento et al., 2011; Lucas et al., 2010; Sirianni et
al., 2008). Studies with the mouse spermatogonial GC-1 cell line demonstrated
E2 rapidly activates the EGFR through a crosstalk between GPER and classical
ERs, leading to cell proliferation (Sirianni et al., 2008). In rat Sertoli cells,
activation of GPER induces transactivation of the EGFR via Src, MMPdependent cleavage of HB-EGF, and MAPK activation (Lucas et al., 2010).
GPERs role in regulation of apoptosis has also been described (Lazari et al.,
2009), and is shown to involve E2-mediated increase in antiapoptotic protein
BCL2 and decrease in the proapoptotic protein BAX (Lucas et al., 2010).
Because of the profound effects of E2 on male reproductive function,
including in the testes and epididymis, together with the fact that GPER is found
to be expressed in the testes (Lucas et al., 2010; Rago et al., 2011), we
investigated the role of GPER in mediating physiologic functions of E2 in the
testes and epididymis. It has been shown that certain mice strains are more
susceptible to E2-induced disruption of male reproductive development. Spearow
and colleagues compared the effects of juvenile E2 exposure on testes weight,
development and spermatogenesis in three different strains of mice, including
CD-1 from Charles River, C57BL/6J (B6) from the Jackson Laboratory, and
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several that had been developed from a common base population. C57BL/6 mice
showed a large (greater than 16-fold) susceptibility to E2-disruption of testicular
function when compared to widely used CD-1 mouse line (Spearow et al., 1999).
Based on this study, we chose the C57BL/6 mouse strain to investigate the role
of GPER in E2’s regulation of testicular function.
C57BL/6 male mice were implanted subcutaneously in the scapular region
with slow release pellets (21-day release) containing placebo (sham), E2 (2.1µg),
G-1 (21µg) or G36 (105µg) at day 23 of age. A cohort of mice received two
pellets (E2 + G36 or G-1 +G36). At 44 days of age (21 days post-pellet insertion),
mice were euthanized and male reproductive organs including testes and
epididymis were removed and analyzed to determine E2-and G-1-induced
changes is weight, morphology and presence of mature sperm.
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4.3 Results
4.3.1 Pubertal exposure to estrogen reduces testes size and wet weight in mice.
As E2 is known to induce a reduction in testicular size and wet weight
(Spearow et al., 1999), we were interested if GPER mediates this effect. After
mice had been euthanized, yet before dissection of the male reproductive
organs, mice were weighed, and testes were weighed upon removal. Testes from
E2 treated mice appeared much smaller than testes from mice receiving a sham
or G-1 pellet (Fig 4.4). Testes wet weight fwas significantly reduced in E2-treated
mice when compared to sham-treated mice (Fig 4.5). E2’s effect on wet weight
was not inhibited by GPER-selective antagonist G36, nor did G36 alone have an
effect on testes wet weight when compared to mice having received a sham
pellet. Also, G-1 alone, or in combination with G36 had no effect on testes wet
weight when compared to sham treated mice (Fig 4.5).

4.3.2 Estrogen disrupts testicular morphology and spermatogenesis in male
mice.
We were next interested the role of GPER in spermatogenesis (judged by
the presence of mature sperm in the seminiferous tubules at time of death) and
regulation of testicular morphology, since E2 adversely affects both of these
characteristics (Spearow et al., 1999). Testes were fixed, paraffin embedded and
sectioned. Representative images of H&E stained sections from mice receiving
sham (A), E2 (B) or G-1 (C) pellets are shown in figure 4.6. The presence of
sperm in the lumens of these seminiferous tubules is highlighted with arrows
(Figure 4.6 A, C; bottom panel). From the images it is apparent that E2
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abolished sperm production, based on the absence of mature sperm in the
seminiferous tubules of mice that received an E2 pellet (Figure 4.6B). E2
treatment of C57BL/6 mice also resulted in a disruption in proper testicular
morphology (designated with arrowheads in Fig 4.6B, top image). Upon
quantification of spermatogenesis, we found that E2 significantly reduced the
number of sperm per seminiferous tubule lumen compared to sham treated mice,
whereas G-1 had no effect on spermatogenesis (Fig 4.7). G36 was unable to
inhibit the E2-mediated decrease in spermatogenesis. Also, G-1 alone, or in
combination with G36 had no effect on spermatogenesis in male C57BL/6 mice
(Fig 4.7)

4.3.3 G-1 promotes increase epididymal lumen size in male mice
Another E2-responsive organ in the male reproductive system is the
epididymis. The structure of the epididymis, shown in figure 4.3, is similar in
many ways to an alveolar structure found in the mammary gland. Both structures
are tubular, with a central lumen surrounded by a layer of luminal epithelial cell
(termed principal cells in the epididymis). Since G-1-mediated activation of GPER
in human breast tissue resulted in an increase in luminal size in alveolar
structures (Fig 3.3C, 3.4B), we were interested in the effect of E2 and G-1 on
morphologic changes to a similar epithelial structure.
Representative images of H&E stained C57BL/6 epididymal structures
from mice receiving sham (A), E2 (B) or G-1 (C) pellets are shown in Figure 4.8.
E2-induced disruption of morphological structures is seen in the epididymis,
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consistent with observation of disrupted morphology in the seminiferous tubules
(Fig 4.6B); however E2 did not promote changes in luminal area (Fig 4.8A) when
quantitated and compared to sham treated mice (Fig .8A, 4.9). Conversely,
epididymal structures from mice that received a G-1 pellet had significantly larger
lumens (Fig 4.8C) when compared to mice that had received a sham pellet (Fig
4.8A, 4.9); this effect was significantly reduced in mice that had received a G-1
pellet together with a G36 pellet (Fig 4.9).
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4.4 Discussion
The effects of E2 in the male reproductive system have classically been
attributed to ligand-dependent transcription factor receptors ERα and ERβ. E2’s
role on spermatogenesis seems to be a dose dependent effect. E2 is required for
development of the male reproductive system and for proper spermatogenesis,
demonstrated by the lack of proper development and sperm production in
aromatase null and ER-/- mice (Korach, 1994; Lubahn et al., 1993). At high
concentrations; however, E2 has a detrimental effect on spermatogenesis based
on E2’s ability to negatively regulate the hypothalamic-pituitary-testicular axis,
specifically inhibiting FSH and LH secretion from the pituitary (Finkelstein et al.,
1991; Handelsman et al., 2000). The confounding roles of E2 in the male
reproductive system are further complicated by the identification and expression
of a third estrogen receptor, GPER, in the testes (Rago et al., 2011). While some
signaling mechanisms have been characterized in terms of E2-induced activation
of GPER in the testes (Chimento et al., 2011; Lucas et al., 2010; Lucas et al.,
2010), a direct mechanism for GPER-dependent regulation of E2-induced
responses has yet to be elucidated.
For the present study, we were interested in determining GPER’s role in
E2-mediated regulation of testes size and spermatogenesis. Consistent with a
previous report (Spearow et al., 1999), we found that mice receiving E2 pellets
had significantly reduced testes size (Fig 4.4B), wet weight (Fig. 4.5) and
spermatogenesis (Fig 4.6B, 4.7) when compared to control treated mice, and
these effects were not affected by the presence of GPER-selective antagonist
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G36.

This

suggests

that

E2-induced

reduction

in

testes

size

and

spermatogenesis is mediated through classical ERs in the testes and not GPER.
This is confirmed by the fact that G-1 was not able to stimulate a decrease in
testes wet weight (Fig 4.5) or a decrease in spermatogenesis (Fig 4.7) in
C57BL/6 mice that received a G-1 pellet.
In addition to regulation of testicular function, we were also interested in
determining the role of GPER in epididymal regulation by E2. Since the structure
of the epididymis is similar to alveolar structures in the mammary gland, and G-1
stimulated a change in morphology resulting in larger lumens in alveolar
structures in human breast tissue, we used same morphological measurements
to characterize epididymal luminal area in mice that had received sham, E2 and
G-1 pellets. Our results demonstrate that while E2 had no effect on luminal area
within epididymal structures in C57BL/6 male mice, mice receiving G-1 pellets
had statistically significantly larger lumens. The G-1-induced increase in luminal
area was inhibited in mice that received a G-1 pellet in combination with a G36
pellet (Fig 4.9), suggesting that this effect is mediated by GPER.
The ability of G-1 to promote a similar effect (increased lumen size) in two
diverse tissue types (the mammary gland and the epididymis) is not surprising,
since the signaling mechanism downstream of GPER activation is also similar. It
has been shown in breast cancer cells, as well as in normal breast epithelial cells
(Chapter 2) that GPER activation leads to transactivation of the EGFR and
downstream activation of MAPK and PI3K signaling cascades (Filardo et al.,
2000). Similarly, in rat Sertoli cells, GPER has been shown to mediate rapid E2
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signaling, by transactivation of the EGFR through activation of Src, MMPs, and
cleavage of HB-EGF at the cell surface. Our results demonstrate that while
GPER isn’t involved in certain E2-induced processes in the male reproductive
physiology of C57BL/6 mice, including E2-induced decreased testes size and E2induced decreased spermatogenesis, it does play a role in morphological
regulation of the epididymis, similar to its role in regulation of breast epithelial
morphology. Homeostasis of epithelial structures is important in the maintenance
of function of epithelial structures. The epididymis is the final location of sperm
maturation, and thus is a very important organ in male fertility. The ability of
GPER to modulate epididymal morphology suggests that E2-induced activation
of GPER occurs in the epididymis, and may be indicative of a possible role for
GPER in sperm maturation.
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4.5 Materials and Methods
4.5.1 Mouse Models
C57BL/6 male mice were used in this study due to their high sensitivity to
E2 (Spearow et al., 1999). At 23 days of age, slow release pellets containing
placebo (sham), 2.1µG E2, 21µG G-1, or 105 µG G36 were implanted with a
trocar subcutaneously in the scapular region of male C57BL/6 mice. A subset of
mice received two pellets (2.1µ E2 + 105µG G36; 21µG G-1 + 105µG G36).
Pellets were obtained from Innovative Research of America (Sarasota, FL). At 44
days of age, mice were euthanized tissue was collected from mice, including
testes and epididymis. Tissue was fixed with 4% paraformaldehyde.

4.5.2 Histology
Tissue was dehydrated and embedded in paraffin, and sectioned. Paraffin
sections (5µm) were mounted on Super-Frost Plus slides (Menzel- Gläser,
Germany). After rehydrating sections through graded alcohol series followed by
water, tissue was stained with hematoxylin and eosin (H&E) for histological
examination. Images were obtained under light microscopy at x400 magnification
with the aid of a Zeiss 200M Axiovert inverted microscope (Carl Zeiss Inc.,
Oberkochen, Germany) and morphological measurements were made using
metamorph image analysis software (Molecular devices, Union CA).

4.5.3 Morphologic evaluation of Epididymal Lumens
Histomorphometric evaluation was carried out to determine the effects of
different treatments on testicular and epididymal morphology. All morphometric
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measurements were done on H&E-stained sections. Using a digital drawing
system run by Metamorph, cross-sections of epididymal tubules were measured
by outlining epididymal luminal space on the monitor screen with the computer
mouse. Luminal area (µm2) was calculated by tracing the empty space within the
luminal epithelial cells. In each treatment sample, a minimum of 15 epididymal
structures were randomly selected and measured.

4.5.4 Testes Wet Weight/Sperm Quantification
Before tissue collection, mice were weighed. Testes were weighed upon removal
from mice. To determine the testes wet weight measurement, testes weight was
expressed as a percentage of total body weight per mouse. To determine effects
of pellets on spermatogenesis in mice, the number of mature sperm was counted
per each testicular lumen per H&E stained sections. A minimum of 15 testicular
lumens were included per treatment group and is expressed as an average.

4.5.5 Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.03 (La
Jolla, CA). Analysis done with a one-way Analysis of Variance (ANOVA) within
Prism estimates the correlation of variables (spermatogenesis, testes wet weight
and epididymal luminal area) with treatment groups (sham, E2, G-1, G-36, etc).
Pairwise comparisons of results between different treatment groups were
determined using a Dunnett’s test following the one-way ANOVA. Data
represents the mean ± SEM of three independent experiments. P-values less
than 0.05 were considered to be significant.
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4.6 FIGURE LEGENDS
Figure 4.1 Endocrine regulation of testicular cells by the hypothalamicpituitary-gonadal axis.
Gonadotrophin releasing hormone (GnRH) is released from the hypothalamus
which stimulates cells in the anterior pituitary to secrete luteinizing hormone (LH)
and follicle-stimulating hormone (FSH). LH and FSH act on cells in the testes to
stimulate

testosterone

production

and

initiation

of

spermatogenesis.

Testosterone produced in Leydig cells inhibits the hypothalamus from releasing
GnRH, and the pituitary from releasing FSH and LH. Inhibin, produced by Sertoli
cells also inhibits FSH synthesis and secretion.
Figure 4.2 Cross-sectional structure of a mouse seminiferous tubule.
Spermatogenesis, the generation of haploid, mature spermatozoa from diploid
germ cells (spermatogonia), occurs within seminiferous tubules in the testes. The
tubule epithelium consists of Sertoli cells which nurse the maturing sperm,
coordinate spermatogenesis, and synthesize androgen binding hormone which
binds androgens, concentrating it in the tubules. Enveloped by the Sertoli cells
are spermatogenic cells, with the diploid spermatogonia along the external basal
lamina, and successive differentiative stages (primary spermatocytes >
secondary spermatocytes > spermatids > spermatozoa) arrayed toward the
lumen. Leydig cells reside in the interstitial space surrounding seminiferous
tubules and are the site of testosterone synthesis.
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Figure 4.3 Illustration of mouse epididymis.
The epididymis consists of a two-layered pseudostratified epithelium made up of
principal cells and basal cells, thought to be stem or progenitor cells. The
epithelial layer is separated from the underlying connective tissue by a basement
membrane
Figure 4.4 Estrogen reduces testes size in male C57BL/6 mice.
C57BL/6 mice (23 days of age) were implanted subcutaneously with slow release
pellets containing sham (A), 2.1µg E2 (B) or 21µg G-1 (C). After 21 days, testes
were removed. Representative light microscopy images of testes from mice
receiving indicated pellets are shown here.
Figure 4.5 Estrogen reduces testes wet weight in male C57BL/6 mice.
C57BL/6 mice (23 days of age) were implanted subcutaneously with slow release
pellets containing sham, 2.1µg E2, 21µg G-1, 105µg G36, or with both E2 and
G36 or G-1 and G-36. After 21 days, testes were removed. Testes wet weight (D)
was calculated by the weight of the testes upon removal relative to the body
weight of the intact mouse before dissection. Data are representative of three
independent experiments. Results are expressed as mean ± SEM and statistical
significance (P≤ .05) was assessed by one-way ANOVA followed by a Dunnett’s
test. (*, significantly different relative to sham)
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Figure 4.6 Estrogen disrupts testicular morphology and spermatogenesis
in male C57BL/6 mice.
C57BL/6 mice (23 days of age) were implanted subcutaneously with slow release
pellets containing sham (A), 2.1µg E2 (B) or 21µg G-1 (C). After 21 days, testes
were prepared for histology (H&E stain). Arrowheads in B (top image) represent
a disruption in proper testicular morphology that is not seen in sham (A) or G-1
(B) treated mice. Arrows in A and C (bottom images) represent the presence of
mature sperm (dark purple structures are sperm heads) in the testes; not
observed in E2 treated mice (B).
Figure 4.7 Estrogen disrupts spermatogenesis in male C57BL/6 mice.
C57BL/6 mice (23 days of age) were implanted subcutaneously with slow release
pellets containing sham, 2.1µg E2, 21µg G-1, 105µg G36, E2 + G36, or G-1 + G36. After 21 days, testes were prepared for histology. Spermatogenesis was
quantified as the average number of sperm per testicular structure in a minimum
of 15 structures per treatment group (D). Data are representative of three
independent experiments. Results are expressed as mean ± SEM and statistical
significance (P≤ .05) was assessed by one-way ANOVA followed by a Dunnett’s
test. (*, significantly different relative to sham)
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Figure 4.8a G-1 induces an increase in lumen size in male C57BL/6
epididymis.
Luminal area was measured on epididymal epithelial structures from male
C57BL/6 mice treated with pellets containing sham (A), 2.1µg E2 (B) or 21µg G1(C). After 21 days, epididymal tissue was prepared for histology (H&E stain).
Figure 4.8b G-1 induces an increase in lumen size in male.
C57BL/6 epididymis mouse epididymis. Luminal area was measured on
epididymal epithelial structures from male C57BL/6 mice treated with pellets
containing sham, 2.1µg E2, 21µg G-1, 105µg G36, E2 + G36, or G-1 + G-36.
After 21 days, epididymal tissue was prepared for histology. Data are
representative of three independent experiments. Results are expressed as
mean ± SEM, and statistical significance (P ≤ 0.05) was assessed by one-way
ANOVA followed by a Dunnett’s test-test. (*, significantly different relative to
sham; #, significantly different relative to G-1)
Figure 4.8b G-1 induces and increase in lumen size in male C57BL/6
epididymis mouse epididymis.
Luminal area was measured on epididymal epithelial structures from male
C57BL/6 mice treated with pellets containing sham, 2.1µg E2, 21µg G-1, 105µg
G36, E2 + G36, or G-1 + G-36. After 21 days, epididymal tissue was prepared for
histology. Data are representative of three independent experiments. Results are
expressed as mean ± SEM, and statistical significance (P ≤ 0.05) was assessed
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by one-way ANOVA followed by a Dunnett’s test-test. (*, significantly different
relative to sham; #, significantly different relative to G-1)
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4.7 Figures
Figure 4.1 Endocrine regulation of testicular cells by the hypothalamic-pituitary-gonadal
axis
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Figure 4.2 Cross-sectional structure of a mouse seminiferous tubule
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Figure 4.3 Illustration of mouse epididymis
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Figure 4.4 Estrogen reduces testes size in male C57BL/6 mice
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Figure 4.5 Estrogen reduces testes wet weight in male C57BL/6 mice
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Figure 4.6 Estrogen disrupts testicular morphology and spermatogenesis in male C57BL/6
mice
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Figure 4.7 Estrogen disrupts spermatogenesis in male C57BL/6 mice
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Figure 4.8a G-1 induces an increase in lumen size in male C57BL/6 epididymis
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Figure 4.8b G-1 induces an increase in lumen size in male C57BL/6 epididymis mouse
epididymis
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5. SUMMARY AND FUTURE DIRECTIONS
5.1 Summary
In this study, our aim was to determine if GPER contributes to E2-induced
physiologic processes in the breast, including regulation of breast epithelial
proliferation and morphogenesis. E2’s effects mediated through classical ERs
ERα and ERβ are well characterized, with much knowledge acquired through
studies done in ER-/- mice (Couse and Korach, 1999; Feng et al., 2007; Forster
et al., 2002a; Korach, 1994). ERα mediates E2-induced proliferation and
subsequent branching morphogenesis of the mammary gland at puberty, upon
initial exposure to circulating E2 (Brisken and O'Malley, 2010), and ERβ
mediates E2-induced terminal differentiation of the gland in preparation for
lactation at pregnancy (Forster et al., 2002a). The identification and
characterization of a third estrogen receptor has complicated the views of E2
signaling, since this receptor, a G protein–coupled estrogen receptor (GPER),
shares no homology with the classical ERs, which generally function as liganddependent transcription factors [although evidence of rapid E2 signaling
mediated through classical ERs does exist (Kelly and Levin, 2001; Levin, 2002)].
Our goal for this work was to provide evidence for a role for GPER mediation of
the physiologic effects of E2 in female and male reproductive organs; a summary
for each chapter follows.

5.1.1 Chapter 2
As the chief role of E2 in the mammary gland is stimulation of cellular
proliferation, we were interested in the function of GPER in mediating this
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proliferative effect. We demonstrated GPER-dependent, E2-induced proliferation
in three different models, normal human breast tissue cultured ex vivo,
tumorigenic human breast tissue cultured ex vivo, and in a non-transformed
breast epithelial cell line, MCF10A. Comparing normal human breast tissue and
MCF10A cells, one key difference between the two is the expression of ERs.
MCF10A cells only express GPER, thus the observed increased in proliferation
with E2 and G-1 treatment can be attributed to GPER alone, whereas breast
tissue expresses all three ERs (ERα/β and GPER). The ability of GPER-selective
ligand G36 to partially abrogate E2-induced proliferation indicated GPER is
responsible in part for E2-induced proliferation in the breast. We demonstrated
that GPER-induced proliferation is dependent on transactivation of the EGFR by
activation of Src; however MMPs and cleavage of HB-EGF is not required for E2or G-1-induced ERK activation or proliferation in MCF10A cells, suggesting a
possible mechanism for direct intracellular EGFR transactivation by Src,
downstream of GPER. Alternatively, these results can be explained by juxtracrine
activation of EGFR via pro-HB-EGF on the cell surface.
In the third model, the ability of GPER to mediate E2-induced proliferation
in tumorigenic breast tissue is exciting in light of the correlation between GPER
expression in tumors and increased tumor size (Filardo et al., 2006). Based on
our ex vivo results, it is possible to hypothesize that E2 or tamoxifen is promoting
proliferation in tumors in vivo, since tamoxifen is a known agonist for GPER
(Pandey et al., 2009). There is evidence that long term tamoxifen treatment of
breast cancer cells in vitro increases E2 sensitivity, which leads to increased
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GPER expression. Tamoxifen can then act as an agonist for GPER in these
cells, causing transactivation of the EGFR, and ERK phosphorylation, which in
turn promotes the sensitivity of these cells to E2, creating a positive feedback
mechanism (Ignatov et al., 2010). Ignatov and colleagues also observed a
positive correlation between GPER expression and tamoxifen resistance in
primary breast tumors (Ignatov et al., 2011). These observations, taken together
with our own data from chapter 2 (E2-induced proliferation in tumors) suggest
that GPER could be promoting proliferation in breast tumors in response to E2,
and could also be activated by tamoxifen in women who are receiving it as an
anti ER therapy for breast cancer.

5.1.2 Chapter 3
Coupled to E2’s primary role in proliferation is the role of E2 in
morphological regulation of the mammary gland. Morphologic changes in the
gland are initiated by E2-induced, ERα-mediated proliferation (Brisken and
O'Malley, 2010). Since we demonstrated in chapter 2 that GPER-mediates E2induced proliferation in the mammary gland, we sought to determine if E2 and G1-dependent increases in proliferation affect mammary gland morphology. We
observed that E2 leads to increased luminal epithelial cell layers (in normal
alveolar structures there is a single layer) and G-1-led to an increase in the
luminal area within alveolar epithelial structures. In an effort to link proliferation to
changes in morphology, we investigated E2’s and G-1’s ability to regulate mitotic
spindle orientation in MCF10A breast epithelial cells cultured in 3D. We observed
that E2, but not G-1 induced a rotation of the mitotic spindle in proliferating cells,
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therefore E2-promoted a plane of cell division that was perpendicular to the
basement membrane. This could presumably produce alveolar structures with
multiple epithelial layers, consistent with what is observed in E2-treated tissue.
Although G-1 did not alter mitotic spindle orientation, if the majority of the
proliferating mitotic spindles are oriented parallel to the basement membrane,
and proliferation is enhanced due to G-1 treatment, larger lumens could result,
albeit with a single epithelial layer. We also observed in chapter 3 that G-1induces downregulation of E-cadherin in human breast tissue. One mechanism
to regulate E-cadherin-mediated cell-cell adhesion is by phosphorylation of Ecadherin, and this leads to internalization and degradation of E-cadherin (Shen et
al., 2008). FAK and Src are known to interact with one another to mediate
phospho-regulation of cellular targets (Hiscox et al., 2007; Planas-Silva et al.,
2006), which is interesting because we have shown Src to be required for GPERdependent proliferation (chapter 2) and we have also seen a significant increase
in FAK activation with G-1 treatment of MCF01A cells. Based on these results,
it’s not implausible to hypothesize that E2-induced GPER activation and
subsequent Src activation lead to FAK activation, and the Src/FAK kinases
induced downregulation of E-cadherin in alveolar structures, thus loosening the
cell-cell adhesions, allowing for a single-layered epithelial structure that can
accommodate increased proliferation.

5.1.3 Chapter 4
At first glance, chapter four might seem like an outlier in this study, since it
focuses on E2 regulation of a completely different male organ in mice, whereas
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the rest of the thesis work is carried out in female breast tissue and breast
epithelial cells. There are many similarities; however, that can be used to draw
conclusions between chapter 3 and 4. For example, both breast tissue and
testes/epididymal tissue are under tight endocrine control regulated by the
hypothalamus-pituitary-gonad axis (Bliss et al., 2010). Next, there is evidence
that these tissues are subject to regulation by E2, mediated by all three estrogen
receptors (ERα/β and GPER), and lastly, the structure of mammary alveoli is
similar to the structure of the epididymal epithelium (highlighted in chapter 3
discussion); specifically the epididymis consists of an epithelial duct with a single
layer of cuboidal/columnar epithelia surrounding a central lumen. Accordingly, it
is intriguing that G-1 induces a similar effect, increased lumen size, in both the
mammary alveolar epithelium and the epididymal epithelium. Although little has
been reported in terms of GPER-dependent signaling cells in the male
reproductive

system,

initial

observations

suggest

GPER-dependent

transactivation of the EGFR in testicular cells is mediated by activation of Src,
similar to our own data (chapter 2) and previous reports in breast cancer cells
(Filardo et al., 2000).
It is conceivable that GPER exerts other effects in the epididymal
epithelium, for instance downregulation of E-cadherin (similar to the breast
tissue; chapter 3), since E-cadherin is expressed at cell-cell junctions between
the lumen-lining principal cells in the epididymis (Andersson et al., 1994; MarinBriggiler et al., 2008). E2 also plays a role in fluid resorption in the epididymis
and the efferent ductuals. Studies with ER-/- mice reveal that inhibition of fluid
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resorption in the efferent ductuals and the epididymis can lead to inefficient
spermatogenesis because the tubules are full of fluid (Hess et al., 1997). It is
possible that GPER is mediating its effects on epididymal luminal morphology by
inhibiting proper fluid resorption in the male gonads, although the molecular
mechanisms by which GPER elicits effects in the male reproductive tract await
further investigation.
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5.2 OVERALL CONCLUSIONS
In this work, we were able to show a specific requirement for GPER
function in E2-induced proliferation in human breast tissue. This is the first
demonstration of GPER-mediated proliferation in a human tissue. We also
described a novel signaling mechanism in MCF10A cells for GPER-dependent
transactivation of the EGFR, independent of MMP activation and cleavage of cell
surface-bound HB-EGF (which had been previously reported in breast cancer
cells (Filardo et al., 2000; Filardo, 2002). The ability of GPER to mediate E2induced proliferation in normal and tumorigenic breast tissue (chapter 2),
together with its widely reported expression in breast tumors and breast cancer
cell lines (Filardo et al., 2006; Kuo et al., 2007; Luo et al., 2011), and our
observations of GPER-mediated morphological regulation and E-cadherin
downregulation in the mammary epithelium leads to the postulation that this
receptor is certainly involved in physiology regulation of hormone-dependent
tissue and will someday be an effective target in patients with breast or other
hormone responsive tumors.
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